

Université de Montréal

**Intraoperative hemodynamic instability during and after separation from
cardiopulmonary bypass: importance, mechanism and prevention**

par

André-Yvan Denault MD PhD FRCPC ABIM CCM FASE

Département d'anesthésiologie

Faculté de médecine

Thèse présentée à la Faculté des études supérieures
en vue de l'obtention du grade de PhD
en Sciences Biomédicales (3-484-1-0)

Septembre 2009

© André-Yvan Denault, 2009

Université de Montréal
Faculté des études supérieures

Cette thèse intitulée:

Difficult separation from cardiopulmonary bypass:
Importance, mechanism and prevention

Présentée par :
André-Yvan Denault

a été évaluée et défendue le 17 décembre 2009

Pour voir la vidéo de la présentation :

www.mediaenligne.umontreal.ca/medclin/anesth/denault_phd.wmv

par un jury composé des personnes suivantes :

Pierre Beaulieu PhD, président-rapporteur

Jean Lambert PhD, directeur de recherche

Jean-Claude Tardif, co-directeur

Patrick Mathieu, membre du jury

Jean-Yves Dupuis, examinateur externe

François Reeves, représentant du doyen de la FES

Abstract

Every year, 1 million to 1.25 million patients worldwide undergo cardiac surgery. [1] Up to 36,000 cardiac surgeries are performed each year in Canada and close to 8000 in Quebec (<http://www.ccs.ca>). Because of the aging of the population, cardiac surgery will increasingly be offered to patients at a higher risk of complications. Indeed, elderly patients have increased co-morbidities, and aging is also a significant risk factor in the prevalence of coronary artery disease. [2] The consequence is a reduced physiologic reserve, hence an increased risk of mortality. These issues will have a significant impact on future healthcare costs, because our population undergoing cardiac surgery will be older and more likely to develop postoperative complications. One of the most dreaded complications in cardiac surgery is difficult separation from cardiopulmonary bypass (CPB). The definition of difficult separation from CPB includes the time period from when CPB is initiated and until the patient leaves the operating room. When separation from CPB is associated with right ventricular failure, the mortality rate will range from 44% to 86%. [3-7] Therefore the diagnosis, the preoperative prediction, the mechanism, prevention and treatment of difficult separation from CPB will be crucial in order to improve the selection and care of patients and to prevent complications for this high-risk patient population. The hypotheses of this thesis are the following: 1) difficult separation from CPB is an independent factor of morbidity and mortality, 2) the mechanism of difficult separation from CPB can be understood through a systematic approach, 3) inhaled milrinone is a preventive and therapeutic approach in the patient at risk for difficult weaning from CPB after cardiac surgery.

Keywords : Right ventricle; Cardiopulmonary bypass; Cardiac surgery; Hemodynamic instability; Transesophageal echocardiography; Pulmonary hypertension.

Chapter 3 Mechanisms of difficult separation from cardiopulmonary bypass

As we have previously observed, difficult separation from CPB is an important and independent cause of morbidity and mortality. Therefore, it is of crucial importance to understand that mechanism precisely in order to initiate appropriate treatment. Difficult separation from CPB will result in a reduction in cardiac output, which will in turn result in hemodynamic instability. In order to describe this mechanism, the use of the concept of venous return as described by Guyton, [54] combined with that of biventricular pressure-volume relationship, can help us understand this critical condition. The use of TEE has allowed us to document the various causes of hemodynamic instability, and examples from the MHI TEE database ($n = 15,000$ exams) will be used to illustrate this concept.

3.1 Mechanism of hemodynamic instability

The various components of hemodynamic instability can be explained using the classical concept of venous return as described by Guyton. [54] In simple terms, venous return (VR) is determined by a pressure gradient. This gradient corresponds to the difference between the mean systemic venous pressure (Pms) in the periphery and the right atrial pressure (Pra). This pressure gradient difference is divided by the resistance to venous return (Rvr).

$$VR = \frac{Pms - Pra}{Rvr} \quad (\text{Equation 1})$$

Therefore venous return and, consequently, cardiac output, will be reduced if: 1) the right atrial pressure is elevated, 2) the mean systemic pressure is low, and/or 3) the resistance to venous return is increased. There are several ways to illustrate this relationship. The classical approach to describe venous return and cardiac output is illustrated in Figure 13. [156]




Figure 13 Venous return and cardiac output

The venous return and cardiac output (y axis) and its relation with right atrial pressure (x axis) is shown. The intersection of both curves will correspond to the right atrial pressure (P_{ra}) at which, in a steady state, an individual will have an unique venous return and cardiac output. The mean systemic pressure (P_{ms}) corresponds to the point where the venous return = 0. The venous return curve is linked to the resistance to venous return (R_{vr}) (dotted lines) (Adapted from Jacobsohn [156]).

The pressure-volume relationship is used to describe a single cardiac cycle (Figure 14).




Figure 14 Pressure and volume during a cardiac cycle

(A) Changes in aortic, atrial, ventricular pressure, and ventricular volume in relation to the electrocardiogram. Left ventricular (LV) pressure and volume over time during a cardiac cycle is characterized by seven time-related events. Isovolumic contraction [1] is followed by early [2] and late [3] ejection. Diastole starts with isovolumic relaxation, [4] followed by the early filling phase after the opening of the mitral valve, [5] diastasis, [6] and atrial contraction. [7] (B) Corresponding LV pressure-volume relationship during one cardiac cycle (With permission of Denault *et al.* [12]).

The pressure-volume relationship is typically described for the left ventricle but has also been used to evaluate right ventricular function. [157] The major difference between both ventricles is the reduced pressure in the right compared to the left ventricle. [48] In order to integrate the pressure-volume relationship to the venous return concept, we used a simplified alternative approach illustrated in Figure 15.




Figure 15 Venous return and pressure-volume loop concept

The circulatory system can be divided into an intrathoracic and an extrathoracic compartment. Illustrated in red is the arterial system and in blue, the venous system. Most of the blood volume ($\sim 70\%$) lies in the venous system. The mean systemic pressure (P_{ms}) is determined by the stressed volume ($\sim 30\%$ of blood volume). The cardiac pump has two components, the right and the left ventricles, defined by their respective pressure-volume loops (simplified). Both ventricles are connected together through the pericardium and the interventricular septum. The function and interaction between both ventricles will determine right atrial pressure (P_{ra}). Blood returning back to the heart, i.e. venous return, will be dependent on the pressure gradient between the peripheral pressure, or P_{ms} , and the central pressure, or P_{ra} . Furthermore, any conditions increasing the resistance to venous return (R_{vr}), for instance compression of the inferior vena cava, will reduce venous return and consequently cardiac output. (P_a , systemic arterial pressure; R_a , arterial resistance) (With permission of Deslauriers *et al.* [158])

The combination of conventional hemodynamic monitoring and TEE allows the determination of the causes of hemodynamic instability. [44] However, so far, a systematic approach in the diagnosis of difficult separation from CPB using conventional hemodynamic and TEE has not been performed in cardiac surgery. This combined approach can be used to determine the causes of difficult separation from CPB. The causes of hemodynamic instability resulting in reduced venous return or cardiac output and leading to difficult separation from CPB are a reduction in Pms, an increase in Pra and an increase in Rvr (Table 11).

Table 11 Mechanism of hemodynamic instability in cardiac surgery

1) Reduction in mean systemic pressure:

Reduction in stressed volume:

Hemorrhagic shock:

External hemorrhage

Internal: hemothorax, peritoneal hemorrhage, retroperitoneal hemorrhage, gastrointestinal hemorrhage

Increased in compliance

Sepsis and overwhelming shock [137]

Drug-induced vasodilation

Anaphylaxis

Vasoplegic syndrome

Adrenal insufficiency

2) Increased right atrial pressure

Left and right ventricular systolic dysfunction

Left and right ventricular diastolic dysfunction

Left and right outflow tract obstruction

Left and right embolism

Aortic and mitral patient-prosthesis mismatch

Hypoxemia and hypercapnia

Pulmonary reperfusion syndrome

3) Increased resistance to venous return

Compartment syndrome

Pericardial tamponade

Mediastinal: post cardiopulmonary bypass

Pleural: hemothorax and pneumothorax

Abdominal: intrinsic, extrinsic or parietal

Vena cava syndrome

Inferior

Superior

3.1.1 Reduction in mean systemic pressure

The mean systemic pressure, or P_{ms} , will depend on the amount of blood contributing to maintain a specific venous pressure. [156] This can be expressed by the following equation:

$$P_{ms} = \frac{V - V_0}{\text{Compliance of the venous reservoir}} \quad (\text{Equation 2})$$

where V is the total volume of the venous reservoir and V_0 the unstressed volume. The difference between V and V_0 is equal to the stressed volume. Consequently, a reduction in P_{ms} will be caused by a loss of stressed volume, such as hemorrhagic shock, or an increase in compliance of the venous reservoir, such as can be the case following drug-induced vasodilation. Reduction of P_{ms} results in a reduction in venous return and cardiac output from a parallel medial shift of the venous return curve. Pressure and volume of both ventricles will be reduced (Figure 16).




Figure 16 Reduction in mean systemic venous pressure

Reduction in mean systemic venous pressure will result in a medial shift of the venous return curve. In such a situation, pressure and volume of the right and left ventricles will be reduced. This diagnosis can be made with conventional hemodynamic monitoring alone. In such a situation, filling pressure, venous return and cardiac output will be reduced. There are two basic mechanisms: a reduction in the stressed volume and an increase in venous compliance. Both conditions will be associated with a reduction in both left- and right-sided cardiac dimensions; however, some specific echocardiographic findings can suggest rather one mechanism or the other.

3.1.1.1 Reduction in stressed volume

During cardiac surgery, hemorrhagic shock is a common mechanism of reduced Pms that occurs because of a loss of blood volume and, consequently, hemoglobin. Hemorrhagic shock can be defined as internal or external. The latter is easy to diagnose; the former can however prove more difficult to recognize. There are two conditions of internal blood losses that can be diagnosed during cardiac surgery. The first is massive pleural effusion secondary to a hemothorax. We have encountered this condition following traumatic perforation of the superior vena cava during the insertion of a central venous catheter. The diagnosis can easily be made using TEE, as both right and left pleural cavity can be seen using TEE). The mechanism of hemodynamic instability of a hemothorax can also result from an increase in the resistance to venous return, as will be discussed later. In such a situation, right atrial pressure might not be reduced, as the hemothorax can externally compress the right atrium.




Figure 17 Bilateral pleural effusions

(A, B) The left pleural effusion is typically posterior to the descending aorta (Ao) and seen on the right side of the screen. (C,D) The right pleural effusion is on the left side of the screen where part of the liver can be seen. A total of 2500 mL of pleural fluid was removed from the right (900 mL) and left pleural (1400 mL) cavities (With permission of Denault *et al.* [13]).

Another cause of hemodynamic instability easily diagnosed in the operating room is peritoneal hemorrhage. This can result from abdominal aortic or iliac rupture, which can occur during manipulation of these structures. This situation has been encountered during the emergency insertion of an IABP. The diagnosis is based on the new onset of fluid collection in the abdomen. The echocardiographic image is similar to that of ascitis (Figure 18).




Figure 18 Abdominal examination using transesophageal echocardiography

(A,B) Presence of ascitis in a 58-year-old woman. (IVC, inferior vena cava, LHV, left hepatic vein) (Courtesy of Denault *et al.* [13]).

Other sites of bleeding include the gastrointestinal tract and the retroperitoneal space. Such a diagnosis would require other modalities, such as gastrointestinal endoscopy and computed tomography.

3.1.1.2 Increase in venous compliance

The second mechanism involved in a reduction in Pms is an increased compliance of the vascular system. This diagnosis can also be suggested by some specific echocardiographic signs evocative of an infectious process, for instance. Increased venous compliance can develop following the use of several drugs during cardiac surgery, during the vasoplegic syndrome and, in some cases, sepsis. [137]

The use of preoperative angiotensin-converting enzyme inhibitors has been associated with vasodilatory shock in cardiac surgery. [159] In such a case, vasopressin has been proposed as a drug of choice. [160;161] Drug-induced vasodilation can occur shortly following the induction of anesthesia and is often rapidly reversible. Anaphylactic reaction can also occur, particularly during the administration of blood products, aprotinin and protamine, and in patients previously exposed to these agents. Adrenaline or even vasopressin can be used in such a situation. [162] Similarly, the administration of protamine can be associated with acute pulmonary hypertension combined with right ventricular failure. [163] In these situations heparine, methylene blue [163] or inhaled prostacyclin [164] have been used to manage unstable patients. Patients exposed to or under corticosteroids can also present a predisposition to adrenal insufficiency, another cause of increased venous compliance. [165]

The term “vasoplegic syndrome” has been used to describe a severe systemic inflammatory response syndrome occurring after CPB [166] and, in rare instances, in patients without CPB. [136] Vasoplegic syndrome is defined as a mean arterial pressure < 60 mmHg, a cardiac output greater than 4.0 L/min, and low systemic vascular resistance (600 dyne/s/cm^5) under an intravenous norepinephrine infusion ($0.5 \text{ } \mu\text{g/kg/min}$). [167] This condition can occur in up to 5% of patients undergoing cardiac surgery and is associated with an increased morbidity and mortality going up to 5.6%. Treatment with methylene blue has been shown to be effective in 94% of cases. [167] The mechanism of the vasoplegic syndrome is thought to be related to surgical trauma, contact of blood

This is equivalent to 130 mL/hr of norepinephrine (4 mg/250 mL) for a 70 kg patient.

components with the artificial CPB circuit and lung reperfusion injury. [168] This effect will trigger a cytokine-mediated activation of platelets and leukocytes. Both tumor necrosis factor α (TNF- α) and interleukin-6 levels are related to the degree of surgical stress. [169] A high level of TNF- α will promote the secretion of nitric oxide (NO) and platelet-activating factor (PAF). The release of NO will reduce systemic vascular resistance and increase compliance; PAF is partially responsible for the increased permeability in sepsis and shock. [170]

Finally, emergency operation in patients already hemodynamically unstable on vasoactive medication is a well-known risk factor for LCOS [75;78] and mortality. [141] These patients may already show an increase in venous compliance from sepsis. Active endocarditis for instance, with the associated sepsis, is an important predictor of outcome in the Parsonnet score [100] and EuroSCORE. [101;141] In such conditions, the requirement for vasoactive medication can be the result not only of an increased venous compliance but is also often associated with other mechanisms.

3.1.2 Increased right atrial pressure

Increased right atrial pressure can result from left and right systolic dysfunction, diastolic dysfunction, outflow tract obstruction and embolism. In addition, certain biochemical conditions can increase pulmonary vascular resistance, such as hypoxemia, hypercapnia and the pulmonary reperfusion syndrome (see Chapter 6). Aortic and mitral patient-prosthesis mismatch are other factors that can contribute to an increase in right atrial pressure. These conditions, along with their definitions, mechanisms and echocardiographic signs, will be reviewed.

3.1.2.1 Left ventricular systolic dysfunction

One of the most common causes of elevated right atrial pressure is left ventricular systolic dysfunction. During cardiac surgery, left ventricular systolic dysfunction can result from ischemia, poor protection during CPB and air embolism. In a situation where systolic

dysfunction appears either to the left or the right, a right-sided (or lateral) shift of the pressure-volume relationship will be observed. Biventricular volumes will be increased, while ventricular pressure is typically normal or high (Figure 19).




Figure 19 Biventricular systolic dysfunction

Biventricular systolic dysfunction will be associated with a reduction in venous return and cardiac output. The right atrial pressure will increase. In that situation, the pressure and volume of the right and left ventricles will shift laterally.

Echocardiographically, signs of left ventricular dysfunction include a reduced left ventricular ejection fraction measured either using a mid-esophageal view (Figure 20) or transgastric view (Figure 21).




Figure 20 Simpson's method of discs

Measurement of left ventricular volumes by modified Simpson's biplane method using mid-esophageal four- (A,B) and two-chamber (C,D) views. The calculated echocardiographic stroke volume (SV) was slightly different from the SV measured with thermodilution (TD) (EDV, end diastolic volume; EF, ejection fraction; ESV, end systolic volume). (With permission of Denault *et al.* [13])




Figure 21 Left ventricular fractional area change

Measurement of fractional area change (FAC) in a 75-year-old man with unstable angina undergoing emergency revascularization. A transgastric mid-papillary view of the left ventricle (LV) in diastole (A,B) and in systole (C,D) provides the measurements to calculate the FAC, which was 26%. Note the exclusion of the papillary muscles during tracing of the areas. (EDA, end diastolic area; ESA, end systolic area). (With permission of Denault *et al.* [12])

Left ventricular systolic dysfunction originating from either coronary artery disease, cardiomyopathy, or associated with valvular heart disease, will be associated with an elevated left ventricular filling pressure and, consequently, post-capillary pulmonary hypertension. In cardiac surgery, left ventricular systolic dysfunction can be present before or after the procedure.

When present before the procedure, left ventricular systolic dysfunction, defined as reduced LVEF or associated with regional wall motion abnormalities (RWMA), is a known predictor of perioperative mortality in cardiac surgery. [73] This observation was well described in the Coronary Artery Surgery Study (CASS) in 1983. [171] This study

analyzed 7658 patients who underwent isolated coronary revascularization, irrespective of age, and examined whether an age of 65 years or older was an independent predictor of perioperative mortality. The variables selected, in order of significance, were: congestive cardiac failure score; left main coronary artery stenosis and a left-dominant circulation; age of 65 years or older; left ventricular wall motion score; gender; and history of unstable angina pectoris. [171] When left ventricular dysfunction before cardiac surgery is associated with mortality, the mechanism involved is most likely hemodynamic instability. Indeed, in a smaller study of 128 patients undergoing coronary revascularization, Royster *et al.*, [58] using logistic regression analysis, observed that LVEF was significantly lower and the most significant factor ($p = 0.0022$) associated with the requirements for inotropes after cardiac surgery.

Left ventricular dysfunction can occur after cardiac surgery and will be associated with a worse outcome. Leung *et al.* [172] found that postoperative RWMA, as demonstrated by TEE, was the most reliable predictor of operative outcome. Six of 18 patients with postoperative RWMA had an adverse outcome, defined as myocardial infarction, severe left ventricular dysfunction requiring inotropic therapy, or cardiac death, whereas none of the 32 patients without postoperative RWMA showed any adverse outcome.

In summary, reduced left ventricular dysfunction is associated with worse outcome after cardiac surgery when it is present before or after the procedure. Post-capillary pulmonary hypertension is the consequence of left ventricular dysfunction; however, an elevation of LVEDP will appear before elevated left atrial pressures reach the pulmonary circulation. In addition, elevated LVEDP can be present without reduced left ventricular systolic function. This condition is named left ventricular diastolic dysfunction.

3.1.2.2 Left ventricular diastolic dysfunction

Diastolic dysfunction is evaluated and diagnosed by an accepted classification and recommended guidelines (Figure 22). [173;174] These guidelines are based on Doppler signals obtained at the mitral valve leaflet, namely the transmitral flow (TMF) early (E) and


atrial (A) velocities, the pulmonary venous flow (PVF) systolic (S) and diastolic (D) velocities and the myocardial wall velocities measured at the mitral annulus, so-called the mitral annular velocities (MAV). The latter are composed of Em (early component of the MAV) and Am (late or atrial component of the MAV). In patients undergoing cardiac surgery, we have used the following criteria to define diastolic function: normal (TMF E/A >1, PVF S/D >1, MAV Em/Am >1), mild diastolic dysfunction (E/A < 1, S/D >1, MAV Em/Am <1), moderate diastolic dysfunction (E/A ≥ 1, S/D <1, MAV Em/Am <1), and severe diastolic dysfunction (E/A >2, S/D <1, MAV Em/Am < or >1).

	Normal Diastolic Function	Stage 1 Impaired relaxation	Stage II Pseudonormal	Stage III Reversible Restrictive	Stage IV Fixed Restrictive
MITRAL INFLOW	$0.75 < E/A < 1.5$ $DT > 140 \text{ ms}$ 	$E/A < 0.75$ 	$0.75 < E/A < 1.5$ $DT > 140 \text{ ms}$ 	$E/A > 1.5$ $DT < 140 \text{ ms}$ 	$E/A > 1.5$ $DT < 140 \text{ ms}$
PULMONARY VENOUS FLOW	$S \geq D$ $AR \text{ dur} < A \text{ dur}$ 	$S > D$ $AR \text{ dur} < A \text{ dur}$ 	$S < D$ or $AR \text{ dur} > A \text{ dur} + 30 \text{ ms}$ 	$S < D$ or $AR \text{ dur} > A \text{ dur} + 30 \text{ ms}$ 	$S < D$ or $AR \text{ dur} > A \text{ dur} + 30 \text{ ms}$
COLOR M-MODE PROPOGATION VELOCITY	$Vp > 45$ 	$Vp < 45$ 	$Vp < 45$ 	$Vp < 45$ 	$Vp < 45$
DOPPLER TISSUE IMAGING OF MITRAL ANNULAR MOTION	$E/Em < 10$ 	$E/Em < 10$ 	$E/Em \geq 10$ 	$E/Em \geq 10$ 	$E/Em \geq 10$
LV RELAXATION	Normal	Impaired	Impaired	Impaired	Impaired
LV COMPLIANCE	Normal	Normal to ▼	▼▼	▼▼▼	▼▼▼▼
ATRIAL PRESSURE	Normal	Normal	▲▲	▲▲▲	▲▲▲▲

Figure 22 Echocardiographic classification of diastolic dysfunction

(A, peak late diastolic transmitral flow velocity; A dur, duration of mitral inflow A-wave; AR dur, peak pulmonary venous atrial reversal flow velocity duration; D, peak diastolic pulmonary venous flow velocity; DT, deceleration time; E, peak early diastolic transmitral flow velocity; Em, peak early diastolic myocardial velocity; LV, left ventricular; S, peak systolic pulmonary venous flow velocity; Vp, flow propagation velocity). (With permission of Denault *et al.* [12]).

Diastolic dysfunction of both the left and right ventricles will be associated with a normal or reduced volume requiring an increased filling pressure (Figure 23).



Diastolic dysfunction




Figure 23 Biventricular diastolic dysfunction

Biventricular diastolic dysfunction will be associated with a maintained venous return and cardiac output. However, the right atrial pressure will increase from a parallel rightward shift of the venous return curve. In that situation, the filling pressure will increase and ventricular volume can be normal or reduced.

The recognition that left ventricular diastolic dysfunction plays a central role in the pathophysiology of cardiac disease has been compared to the discovery of the Rosetta Stone, which played a key role in understanding 1000 years of Egyptian history. [175] This new understanding was triggered by developments in echocardiography that allowed for a simple, rapid and non-invasive assessment of cardiac function. However, before echocardiography was routinely used in cardiology, several clinicians observed that elevated LVEDP *per se* was associated with mortality. In 1983, in the CASS study, Gersh *et al.* [171] reported their results on 1086 patients of 65 years of age or older who underwent isolated coronary artery bypass grafting. Using a stepwise linear discriminant analysis, the authors identified five variables predictive of perioperative mortality. The first was the presence of 70% or more stenosis of the left main coronary artery and a left-dominant circulation, and the second most important factor was LVEDP.

There is a growing interest in the evaluation of diastolic dysfunction. Diastolic dysfunction is associated with reduced survival in patients with congestive heart failure, [176;177;177-179] sepsis [180] and following acute myocardial infarction. [181;182] This is consistent with the observation that preoperative elevated LVEDP increases the incidence of postoperative inotropic support [58;104] and mortality. [8;11;183] It also supports the hypothesis that diastolic dysfunction before cardiac surgery could have an impact on survival and postoperative complications. [17;39;155;184;185]

The hypothesis that patients with diastolic dysfunction are at higher risk of hemodynamic instability after cardiac surgery is supported by a study by Bernard *et al.* [17] that included 66 patients, of whom 52 underwent coronary revascularization alone. The factors associated with an increased need for vasoactive support after CPB were: female gender, diastolic dysfunction and prolonged duration of CPB. Diastolic dysfunction was more significant than systolic dysfunction in predicting difficult separation from CPB and vasoactive requirement after surgery. The importance of preoperative diastolic dysfunction as an independent predictor of hemodynamic complications and survival in cardiac surgery was reconfirmed by four other investigations. [39;155;184;185]

In summary, diastolic dysfunction will predispose to hemodynamic instability because the impairment of the left ventricle to accommodate volume and the consequent elevated LVEDP can predispose to pulmonary edema, pulmonary hypertension and right ventricular dysfunction. Finally, when hemodynamic instability occurs after cardiac surgery, it is almost invariably associated with filling abnormalities. [19]

3.1.2.3 Right ventricular systolic dysfunction

There are several ways to evaluate right ventricular function, and these methods were reviewed by Haddad *et al.* [48] Right ventricular function is commonly measured with 2D or Doppler echocardiography following published guidelines. [186] Right ventricular fractional area change (normal $\geq 35\%$) (Figure 24), right ventricular myocardial performance index (Figure 25) and tricuspid annular plane systolic excursion (Figure 26) [44] can be obtained to evaluate right ventricular function. The right ventricular myocardial performance index is stratified as $<$ or $\geq 50\%$, as previously described. [187;188]




Figure 24 Right ventricular systolic and diastolic function

A 65-year-old man with previous inferior myocardial infarction scheduled for coronary revascularization. (A–C) Before cardiopulmonary bypass (CPB) the ejection fraction of the left ventricle (LV) is 20% with a low cardiac index of 1.5 L/min per m². (A) Pulsed wave Doppler hepatic venous flow (HVF) shows systolic flow (S) predominance. (B) Tricuspid annular velocities (TAV) by tissue Doppler shows a E_t/A_t ratio < 1 ($E_t = 5.7$ and $A_t = 11.5$ cm/sec). Both suggest mild diastolic dysfunction of the RV. (C) The fractional area change (FAC) of the RV is 34%. (D–F) Post-CPB. (D) The HVF showed new blunting of the systolic flow. (E) The TAV are increased with a similar ratio ($E_t = 7.1$ and $A_t = 12.1$ cm/sec). This suggests decreased RV compliance. (F) Right ventricular FAC increased to 48% consistent with the surgeon's visual appreciation of improved right ventricular function. Upon arrival to the intensive care unit, the cardiac index was 3.0 L/min per m² (AR, atrial reversal; EDA, end-diastolic area; ESA, end-systolic area; LA, left atrium; RA, right atrium). (With permission of Denault *et al.* [12])




Figure 25 Myocardial performance index (MPI)

Measurement of MPI or Tei index. (1) For the MPI of the left ventricle (LV), the transmitral inflow is used for measurement of the duration “a” from the end of atrial contraction (A-wave) to the beginning of LV filling (E-wave). (2) The ejection time (ET) or “b” is measured from a deep transgastric long-axis view Doppler interrogation of the left ventricular outflow tract. The MPI of the right ventricle (RV) is similarly obtained using the transtricuspid flow and the mid-esophageal ascending aorta short-axis view for the right ventricular outflow tract (IVCT, isovolumic contraction time; IVRT, isovolumic relaxation time). (With permission of Denault *et al.* [12])




Figure 26 Tricuspid annular plane systolic excursion (TAPSE)

Steps in the measurement of the TAPSE measured using anatomic M-mode. First a four-chamber view is obtained (A-B). Then the M-mode cursor is positioned along the plane of the TAPSE motion (C). An M-mode figure of this excursion or displacement is obtained (D). The lower point corresponds to the maximal systolic excursion and the upper point is the atrial contraction. The TAPSE is equal to the total systolic excursion of the tricuspid annulus (E). Normal TAPSE should be 20-25 mm. (With permission of Denault *et al.* [12])

Right ventricular systolic dysfunction can be associated or not with left ventricular systolic dysfunction. The mechanism of biventricular systolic dysfunction was illustrated in Figure 27. However, isolated right ventricular systolic dysfunction can lead to left ventricular diastolic dysfunction and left ventricular outflow tract obstruction (Figure 27). In severe cases, this can lead to the opening of a patent foramen ovale and worsening hypoxemia. Hypoxemia will further increase pulmonary hypertension and thus lead to a deterioration of the right ventricular function if the cycle is uninterrupted.

There is growing evidence that morbidity and mortality associated with pulmonary hypertension (discussed in more detail in Chapter 6) are dependent on right ventricular adaptation to disease rather than on the absolute value of pulmonary arterial pressure. [46;189-191] Survival and outcome in idiopathic pulmonary arterial hypertension are more related to elevated mean right atrial pressure and reduced cardiac output than to pulmonary arterial pressure values alone. [189;192]




Figure 27 Isolated right ventricular systolic dysfunction

Isolated right ventricular systolic dysfunction (A) can alter the geometry of the left ventricle via the common pericardium and the interventricular septum through 2 mechanisms. The most frequent is a filling abnormality (B). This is associated with a reduction in left ventricular volume and an increase in left ventricular pressure. The second mechanism can appear in very severe right ventricular dysfunction. This will also be associated with a reduction in left ventricular volume, an increase in left ventricular pressure but also left ventricular outflow tract obstruction (C). In the latter situation, the use of inotropes could exacerbate the left ventricular outflow tract obstruction.

The importance of right ventricular function in cardiac surgery has been demonstrated in a variety of clinical settings such as high risk coronary or valvular heart disease, congenital heart disease, heart transplantation, in patients requiring mechanical assist devices and in the unstable postoperative patient (Table 12).

Table 12 Prognostic value of right ventricular function in cardiac surgery

Study	Population	Study Design	RV dysfunction	Results
Reichert <i>et al.</i> [3]	Unstable postoperative patients	Prospective <i>n</i> = 60	RVFAC < 35%	RV dysfunction associated with high mortality rates
Pinzani <i>et al.</i> [193]	Mitral and combined mitro-aortic surgery	Retrospective <i>n</i> = 382	Clinical definition	Postoperative RV failure is the strongest predictor of postoperative mortality
Cullen <i>et al.</i> [194]	Tetralogy of Fallot	Prospective <i>n</i> = 35	Restrictive RV physiology	Restrictive physiology predicts longer intensive care unit stay post repair and lower cardiac output
Gatzoulis <i>et al.</i> [195]	Tetralogy of Fallot	Prospective <i>n</i> = 41	Restrictive RV physiology	Restrictive physiology predicts smaller RV and better exercise tolerance
Kromos <i>et al.</i> [196]	LVAD and RV failure	Retrospective <i>n</i> = 31	Clinical mean RVEF = 11.8%	Preoperative clinical factors such as fever, pulmonary edema, and intraoperative blood transfusions were associated with RVAD need
Hosenpud <i>et al.</i> [197]	Heart Transplantation	Retrospective International Society for Heart & Lung transplantation <i>n</i> = 69,205	RV failure associated with circulatory failure	RV failure accounts for up to 20% of early deaths

Study	Population	Study Design	RV dysfunction	Results
Oehai <i>et al.</i> [6]	LVAD	Retrospective <i>n</i> = 245	RV failure requiring RVAD	23 patients (9%) required RVAD. The need for circulatory support, female gender, and non-ischemic etiology were predictors of RVAD need.
Maslow <i>et al.</i> [112]	CAD undergoing coronary bypass surgery with LVEF < 25%	Retrospective <i>n</i> = 41	RVFAC < 35%	RV dysfunction is associated with decreased long term survival
Therrien <i>et al.</i> [198]	Tetralogy of Fallot	Prospective <i>n</i> = 17	RV remodeling	Severe RV dilatation (RVEDV > 170 mL/m ² or RVESV > 85 mL/m ²) associated with incomplete RV remodeling
Webb <i>et al.</i> [199]	Atrial septal defect	Retrospective series	RV remodeling	Older age at repair and abnormal RV myocardial relaxation were associated with incomplete RV remodeling
Denault <i>et al.</i> [38]	Patients undergoing bypass surgery	Retrospective and prospective <i>n</i> = 800	Dynamic obstruction of RVOT (Gd > 25 mmHg)	Incidence: 4%, dynamic obstruction of RVOT was associated with a higher incidence of difficult weaning from bypass
Haddad <i>et al.</i> [46]	High-risk valvular surgery	Prospective <i>n</i> = 50	RVFAC < 32% or RVMPI > 0.50	Preoperative RV dysfunction was associated with a higher incidence of postoperative circulatory failure

CAD: coronary artery disease, Gd: gradient, LV: left ventricular, LVAD: left ventricular assist device, RV: right ventricular, RVAD: right ventricular assist device, RVES: right ventricular end-systolic volume, RVED: right ventricular end-diastolic volume, RVEF: right ventricular ejection fraction, RVFAC: right ventricular fractional area change, RVMPI: right ventricular myocardial performance index, RVOT: right ventricular outflow tract obstruction (From Haddad *et al.* [49])

However, most of the evidence that supports the importance of right ventricular function is based on retrospective or small prospective studies. To date, parameters of right ventricular function have not been included in large-scale risk stratification models and therefore their incremental value to the Parsonnet score or the EuroSCORE have not been well established. [100;103;200;201] A recent panel from the National Institutes of Health has stressed the importance of research in the understanding of right ventricular failure. [191] Right ventricular dysfunction can be present before or after the surgical procedure.

In patients presenting with severe aortic stenosis, Boldt *et al.* [202] have demonstrated that preoperative right ventricular dysfunction was associated with a greater requirement of postoperative inotropic support. In a retrospective study including patients undergoing mitral and mitral-aortic valvular surgery, Pinzani *et al.* [193] demonstrated that preoperative right ventricular failure was associated with perioperative mortality. In this same study, postoperative right ventricular failure was the most important independent predictor of late survival. In a small prospective study of 14 patients with severe non-ischemic mitral regurgitation and high-risk descriptors (LVEF \leq 45% or RV ejection fraction (RVEF) \leq 20%), Wencker *et al.* [203] found that preoperative RVEF \leq 20% predicted late postoperative death. In patients undergoing coronary revascularization, Maslow *et al.* [112] showed that right ventricular dysfunction defined by a right ventricular fractional area change (RVFAC) of less than 35% in the context of severe left ventricular systolic dysfunction (LVEF \leq 25%) and non-emergent coronary revascularization was associated with an increased risk of postoperative morbidity and mortality. In this retrospective study ($n = 41$), patients with right ventricular dysfunction had a higher prevalence of diabetes mellitus and renal disease, as well as a higher incidence of postoperative inotropic or mechanical support, longer intensive care unit and hospital stay and a decreased short-term and long-term survival.

The presence of right ventricular failure after CPB is associated with a mortality rate ranging from 44% to 86%. [4] The incidence of post-cardiotomy acute refractory right ventricular failure ranges from 0.04 to 0.1%. Acute refractory right ventricular failure has also been reported in 2-3% patients after a heart transplant and in almost 20-30% patients

who received a left ventricular assist device support, with a reported initial salvage rate of only 25-30%. [5]

3.1.2.4 Right ventricular diastolic dysfunction

The mechanism of right ventricular diastolic function was illustrated in Figure 23. Normal right ventricular diastolic function [204] is defined using normal values reported for Doppler transtricuspid flow early (E) and atrial (A) velocities, [205] hepatic venous flow (HVF) systolic (S), diastolic (D) and atrial reversal (AR) velocities [113;114;206] and tissue Doppler imaging (TDI) of the tricuspid annulus. [207;208] The latter are composed of the Et (early component of the TDI) and At (late or atrial component of the TDI). Right ventricular diastolic function is classified as normal (TTF E/A >1, HVF S/D >1, Et/At >1), mild diastolic dysfunction (E/A <1, or reversed AR >50% of S wave measured on HVF, or Et < At when both E/A and S/D >1), moderate diastolic dysfunction (E/A \geq 1, S/D <1, Et/At <1), and severe diastolic dysfunction (S wave reversal on HVF, irrespective of the E/A and S/D ratio).

Right ventricular diastolic dysfunction could constitute an additional marker to identify populations at higher risk of requiring vasoactive support, and potentially other clinical outcomes. We have previously documented that in hemodynamically unstable patients in the intensive care unit, abnormal right ventricular filling abnormalities were the most common echocardiographic observation. [19] We also noted, in a pilot study, that abnormal hepatic venous flow, when present before cardiac surgery, was associated with an increased need for vasoactive support after cardiac surgery. [34] In these two previous studies, patients were also not graded according to the severity of right ventricular diastolic dysfunction; however, in a recent study, [39] we were able to confirm that moderate to severe right ventricular diastolic dysfunction is associated with lower cardiac index and an increased risk of difficult separation from CPB.

3.1.2.5 Left ventricular outflow tract obstruction

With the increasing use of echocardiography, both in the operating room and in critically ill patients, left ventricular outflow tract obstruction (LVOTO) is being diagnosed more frequently. Left ventricular outflow tract obstruction can be defined as an obstruction to blood flow, either fixed or dynamic, usually located below the aortic valve but sometimes involving regions up to the ventricular apex. The term mid-cavitary or apical obstruction is then used. [209;210]

The diagnosis of LVOTO is critical because although the clinical manifestations are similar to those of left ventricular systolic dysfunction, the treatment and management are based on a completely different rationale. [211] Indeed, inotropic support, pharmacological or mechanical afterload reduction, and volume restriction used in heart failure would significantly deteriorate the hemodynamics of a patient presenting with a low output state resulting from LVOTO. Despite known risk factors for LVOTO, such as ventricular septal thickness > 13 mm, long posterior mitral leaflet, anteriorly displaced coaption point and mitro-aortic angle > 90 degrees, [212] we have seen this condition in numerous scenarios and believe that it has the potential to occur in almost every type of hemodynamically unstable patient presenting with a significantly reduced left ventricular preload. In LVOTO, elevated left ventricular filling pressure will be present with flow turbulence in the left ventricular outflow tract. In some patients, this turbulence can lead to a suctioning (Venturi effect) or drag effect [213] of the anterior leaflet of the mitral valve into the left ventricular outflow tract, the so-called SAM: systolic anterior motion. This will lead to mitral regurgitation, which is typically excentric (Figure 28).




Figure 28 Dynamic left ventricular outflow tract (LVOT) obstruction

Mid-esophageal long-axis view in a 38-year-old man with hemodynamic instability. (A, B) Part of the anterior mitral valve leaflet is obstructing the LVOT. (C, D) This was associated with mitral regurgitation (MR). His hemodynamic condition improved with fluid and β -blockade (Ao, aorta; AoV, aortic valve; LA, left atrium; LV, left ventricle; SAM, systolic anterior motion). (With permission of Denault *et al.* [12])

The consequence of a left or right ventricular outflow tract obstruction will be a reduction in stroke volume and cardiac output with an elevated filling pressure (Figure 29).




Figure 29 Ventricular outflow tract obstruction

Ventricular outflow tract obstruction of the right or left ventricle will be associated with a reduced venous return and cardiac output. The right atrial pressure will increase along the axis of the venous return curve. In that situation, the filling pressure will increase significantly and the ventricular stroke volume will be reduced.

Two types of LVOTO can be clinically present: one is dynamic and the other will have underlying structural anatomical abnormalities such as those observed in hypertrophic obstructive cardiomyopathy or extrinsic mechanical compression. In the dynamic form,

tachycardia and preload reduction will predispose to LVOTO. The dynamic form has been observed in aortic valve replacement, in mitral valve repair and in the critically ill patient (Figure 28).

In aortic stenosis, abnormal systolic intraventricular flow velocities can be observed reaching 14% and are aggravated with inotropes and vasodilators. [214] Aortic valve replacement for aortic stenosis in a patient with pre-existing left ventricular hypertrophy can cause significant SAM in the postoperative period. This results from the acute reduction in afterload, which allows increased left ventricular ejection in a small left ventricular outflow tract, thereby producing subvalvular stenosis or mid-ventricular obstruction. [12] This is usually transient and responds well to volume loading and cessation of inotropic drugs. However, in certain cases, surgical correction may be required (Figure 30). [215]




Figure 30 Left ventricular outflow tract obstruction (LVOTO).

A 53-year-old man with LVOTO after aortic valve replacement. (A,B) The mid-esophageal long-axis view showed the LVOTO secondary to left ventricular septal hypertrophy. (C)

Systemic hypotension was associated with the appearance of a giant “V” wave on the wedged pulmonary artery pressure (Ppa); tracing occurred as the patient was weaned from cardiopulmonary bypass. The “V” wave was secondary to mitral regurgitation from abnormal systolic anterior motion (SAM). This patient did not respond to medical therapy and underwent mitral valve replacement (Ao, aorta; LA, left atrium; LV, left ventricle; Pa, arterial pressure). (With permission of Denault *et al.* [12])

Systolic anterior motion can also occur after MV repair for prolapse. This complication must be specifically looked for while in the operating room after surgery. The incidence of LVOTO after mitral valve repair varies from 2% to 14% [216] and is more frequent with myxomatous changes involving both leaflets. The underlying mechanisms include the anterior displacement of the coaptation point, as well as a longer and redundant posterior leaflet (with or without a more acute mitro-aortic angle), causing the mitral valve apparatus to be displaced toward the LVOT and be dragged by the outflow, provoking a typical SAM and subsequent subvalvular obstruction. Preoperatively, a longer posterior leaflet compared to the anterior leaflet (anterior/posterior length ratio ≤ 1.3) and a shorter distance (≤ 2.5 cm) between the coaptation point and the septum are predictors of SAM development post-repair (Figure 31). [212] For some patients, the problem can be alleviated by increasing LV filling or reducing inotropic support. However, other patients require mitral valve replacement or subsequent repair. The sliding technique has been developed to decrease the incidence of this complication by reducing the posterior leaflet redundancy. [217]




Figure 31 Risk factors of systolic anterior motion (SAM)

(A,B) Measurements to assess the risk for postoperative systolic anterior motion (SAM) after septal resection from a mid-esophageal four-chamber view (AML, anterior leaflet length; Ao, aorta; LA, left atrium; LV, left ventricle; PML, posterior leaflet length; RA, right atrium; RV, right ventricle; SAM, systolic anterior motion; SLCL, septal to leaflet coaptation length). (Adapted with permission of Denault *et al.* [12])

Finally, when using TEE in a series of 61 adults with unexplained hypotension for more than one hour in the intensive care unit, Heidenreich *et al.* [218] observed that LVOTO was present in 3% of patients.

Among the mechanical or extrinsic etiology of LVOTO, in some patients, right ventricular failure can predispose to LVOTO, as previously discussed (Figure 27). In this situation, right ventricular dilatation will reduce the filling of the left ventricle, thus leading

to LVOTO. This is a very difficult situation to manage, as right ventricular dysfunction is associated with poor outcome in numerous scenarios. Inotropic therapy to improve right ventricular function may worsen LVOTO. In such a situation, to improve right ventricular function, we have been using inhaled pulmonary vasodilators, such as prostacyclin or nitric oxide, with good results. [18] Finally, we have also observed extrinsic cardiac obstruction leading to LVOTO in cases such as regional tamponade after cardiac surgery. [12] In these situations, LVOTO will resolve as soon as the underlying cause is removed.

3.1.2.6 Right ventricular outflow tract obstruction

Right ventricular outflow tract obstruction (RVOTO), which can also be due to extrinsic [219-221] or intrinsic causes, [222-224] can also result in hemodynamic instability. According to time-honoured hemodynamic criteria, RVOTO is defined as "significant" when the peak right ventricular to pulmonary artery systolic gradient exceeds 25 mmHg. [225-227] Furthermore, when observed via TEE, significant RVOTO is defined as "fixed" if there is no change in RV outflow tract (RVOT) dimensions during the cardiac cycle with an anatomic substrate for obstruction, and as "dynamic" if RVOT dimensions increase appreciably in diastole. Dynamic RVOTO has been observed in hypertrophic cardiomyopathy [228] and after lung transplantation, [229;230] but it has rarely been described during cardiac surgery. [231]

3.1.2.7 Patient-prosthesis mismatch (PPM)

The indexed effective orifice area for each prosthesis is derived from normal reference values of effective orifice area published in the literature divided by the patient's BSA, as previously described and validated. [120;123;232] Aortic PPM is defined as not clinically significant if the indexed effective orifice area is $> 0.85 \text{ cm}^2/\text{m}^2$, as moderate if it is $> 0.65 \text{ cm}^2/\text{m}^2$ and $\leq 0.85 \text{ cm}^2/\text{m}^2$, and as severe if it is $\leq 0.65 \text{ cm}^2/\text{m}^2$. Mitral PPM is defined as not clinically significant (i.e. mild or no PPM) if the indexed effective orifice area is $> 1.2 \text{ cm}^2/\text{m}^2$, as moderate if it is $> 0.9 \text{ cm}^2/\text{m}^2$ and $\leq 1.2 \text{ cm}^2/\text{m}^2$, and as severe if it is $\leq 0.9 \text{ cm}^2/\text{m}^2$. [128] Moderate to severe aortic or mitral PPM can lead to increased LVEDP, filling

abnormalities (Figure 23), reduced coronary flow reserve, [126] pulmonary hypertension and right ventricular failure (Figure 27). This might explain why patients with PPM show an increase in mortality; however, the link between difficult separation from CPB and PPM has not yet been described.

3.1.2.8 Embolism

Embolism can be directed in the right or the left-sided cardiac chambers. It can be caused by thrombus, air, carbon dioxide or other materials (Figure 7). Right-sided embolism rarely occurs during cardiac surgery but can lead to acute right ventricular failure (Figure 27). Pulmonary embolism secondary to venous thrombus originating from the lower extremity is unusual during cardiac surgery because of the use of heparin. However, after heparin reversal using protamine and with mobilization, patients with predisposing conditions could develop this complication. The presence of mobile thrombus in the right atrium, right ventricle or pulmonary artery is pathognomonic of this condition (Figure 32).




Figure 32 Pulmonary embolism immediately after coronary revascularization

This patient was hospitalized and waiting for more than a week before the procedure could take place. At the end of the procedure, while she was transferred in her bed, she became hemodynamically unstable. A transesophageal echocardiographic exam was immediately performed and showed the appearance of a clot in the right pulmonary artery (A-B). She was brought back to the operating room for urgent embolectomy and the clot was removed (C). She was discharged from the hospital in good condition. (Ao: aorta, RPA: right pulmonary artery, SCV: subclavian vein, SVC: superior vena cava) (Courtesy of Dr. David Bracco and Dr. Nicolas Noiseux).

Air embolism is frequently observed during cardiac surgery and usually has minimal or no consequence when present on the right-sided chambers, unless massive. In such a situation, the diagnosis is based on the appearance of an hyperechoic mobile signal in the right-sided chambers and pulmonary artery. Air will tend to accumulate in the most anterior portion of the right ventricle, i.e. the anterior leaflet of the pulmonic valve (Figure 33).




Figure 33 Air embolism

Air embolism in a 46-year-old woman hemodynamically unstable during spinal surgery in a ventral position. (A,B) She was turned back to a supine position and a mid-esophageal right ventricular outflow view revealed the residual presence of air bubbles on the most anterior aspect of the right ventricle (RV), pulmonary artery (PA) and on both sides of the anterior pulmonic valve (Ao, aorta; LA, left atrium). (Adapted with permission of Denault *et al.* [12])

The presence of air in the left-sided chambers is also common during valvular or open heart surgery. When present, it can lead to right ventricular dysfunction through air embolisation of the right coronary artery. This explains why the de-airing process of the left-sided chambers is of significant importance in valvular surgery (Figure 34).




Figure 34 Air embolism

A 61-year-old woman underwent aortic valve replacement. She was easily weaned from cardiopulmonary bypass (CPB). As she was transferred onto the transportation bed, she developed acute pulmonary hypertension (A) followed by ventricular fibrillation. (B–E) She was resuscitated and a transesophageal echocardiographic exam was performed. A mid-esophageal aortic valve long-axis and short-axis view revealed strong echogenic material close to the prosthetic valve, consistent with air emboli dislodged during mobilization of the patient (Ao, aorta; EKG, electrocardiogram; LA, left atrium; LV, left ventricle; Pa, arterial pressure; PA, pulmonary artery; Ppa, pulmonary artery pressure; Pra,

right atrial pressure; RV, right ventricle; SVC, superior vena cava). (Adapted with permission of Denault *et al.* [12])

Carbon dioxide used during saphenectomy can also inadvertently be directed into the systemic circulation. Carbon dioxide embolism should be suspected when an increase in end-tidal carbon dioxide is followed by a decrease in cardiac output and hypotension. TEE is the most sensitive method to detect gas embolism [233] (Figure 35). We have observed such cases on two occasions. [28;234] Acute right ventricular failure requiring emergency CPB was the consequence of the first case. However, in the second case, the use of inhaled prostacyclin prevented us from using CPB. [28]




Figure 35 Carbon dioxide (CO₂) embolism

Mid-esophageal four-chamber view showing CO₂ embolism in a 69-year-old man undergoing laparoscopic saphenectomy who suddenly became hemodynamically unstable. (A, B) A mid-esophageal four-chamber view showed the appearance of bubbles in the right atrium (RA) and right ventricle (RV) originating from the inferior vena cava. This was associated with right cardiac chamber dilatation. (C) The hemodynamic instability coincided with an abrupt rise in end-tidal CO₂ (LA, left atrium; LV, left ventricle). (Adapted from Martineau *et al.* [28])

3.1.2.9 Hypoxemia and hypercapnia

Both hypoxemia and hypercapnia will lead to pulmonary vasoconstriction, pulmonary hypertension and increased right atrial pressure. This is consistent with the rationale for the Airway-Breathing-Circulation (ABC) method in resuscitation. Airway management and breathing remain the two initial and essential steps in the management of any hemodynamically unstable patient. The effect of hypoxemia is illustrated in Figure 36.




Figure 36 Hemodynamic effect of hypoxemia

Severe hypoxemia in a 48-year-old man observed after coronary revascularization. (A) During the hypoxic episode, the pulmonary artery pressure increased to 61/33 mmHg. (B) Using positive end-expiratory pressure, the hypoxic episode was corrected and the pulmonary artery pressure decreased to 35/25 mmHg. (C) Using near-infrared spectroscopy, the hypoxemia was associated with a reversible reduction in the brain oximetry signal.

Hemodynamic instability through hypoxemia will lead to right ventricular failure and its consequences on left ventricular function (Figure 27). During cardiac surgery, hypoxemia can result from a ventilation-perfusion mismatch or through a right to left shunt. In the latter case, the shunt is typically through a patent foramen ovale. (PFO or “*Trou de Botal*”) present in 20% of the adult population (Figure 37).




Figure 37 Patent foramen ovale (PFO)

(A,B) A PFO demonstrated by color flow Doppler in a mid-esophageal bicaval view. (C,D) Opacification of the right-sided cardiac chambers by intravenous injection of agitated normal saline. During the release phase of the Valsalva maneuver, microbubbles are seen crossing to the left atrium (LA) through a PFO. (With permission of Denault *et al.* [12])

A PFO has a normal amount of tissue when the septum primum is complete, but it does not fuse with the septum secundum to obliterate the foramen ovale. A right to left shunt can be elicited with a Valsalva maneuver. Patency of the foramen ovale can be

anatomically demonstrated with a probe. It usually has no consequences unless it is responsible for a cerebrovascular accident through paradoxical emboli (Figure 38). Some authors, however, suggest that it should be closed if found in a patient in whom a cardiac surgical procedure is performed, [235] but recent evidence suggest no survival benefit. [236] The presence of a PFO may alter the method of venous cannulation in the case of left-sided valve surgery or the need for cardioplegia in right-sided valve surgery. In cases where the patient is at a high risk of hypoxemia post-bypass, such as LVAD insertion and heart transplant, closure of the PFO is warranted.




Figure 38 Paradoxical pulmonary embolism

Paradoxical pulmonary embolism in a 48-year-old man who presented with acute hypotension. (A,B) Mid-esophageal view at 55° showing a thrombus across the patent foramen ovale. (C) Intraoperative aspect of the pulmonary emboli. (D) Autopsy finding of a patent foramen ovale in a patient who died of refractory hypoxemia. (Courtesy of Dr. Michel Pellerin and Dr. Tack Ki Leung) (With permission of Denault *et al.* [12])

Hypercapnia also results in pulmonary vasoconstriction and pulmonary hypertension. The hemodynamic and echocardiographic consequences are the same as those of hypoxemia. [237;238] The effect of hypercapnia can easily be demonstrated during organ donation. In the determination of cardiac death, it is essential to demonstrate the absence of any spontaneous breathing during 10 minutes of apnea. In such a situation, the hemodynamic and echocardiographic effects of hypercapnia can be appreciated (Figure 39). Interestingly, changes in the dimension of the right atrium precede the increase in right atrial pressure (Figure 40). This is most likely secondary to the normal reduced compliance of the right atrial cavity.




Figure 39 Hypercapnia and cardiac function

(A) Tricuspid regurgitation continuous-wave Doppler signal before the apnea testing. The peak pressure gradient is 35.2 mmHg. The pulmonary artery pressure and right atrial pressure were 27/11 and 6 mmHg. (B) After 10 minutes of apnea, the peak pressure gradient increased up to 81.7 mmHg. The pulmonary artery pressure and right atrial

pressure were 82/43 and 12 mmHg. (C) At about the same time, right ventricular and atrial dilatation were present. (D) The right-sided dilatation were reversed once mechanical ventilation was resumed.




Figure 40 Hypercapnia and right atrial dimension and pressure

Relation between the right atrial area and the right atrial pressure (Pra) during apnea testing in organ donation. Initially, the right atrial area increases in size, but at 7 minutes only, the Pra starts to rise, reaching maximal value at 10 minutes. A reduction in right atrial area and Pra was observed when mechanical ventilation was resumed.

In summary, several conditions will contribute to the increase in right atrial pressure. The use of TEE is essential in the diagnosis and treatment of these various conditions. If there is no evidence of altered Pms or Pra, then the next step is to rule out any increase in resistance to venous return.

3.1.3 Increased resistance to venous return

There are two mechanisms of increased resistance to venous return: the first is the extrinsic compression of the circulatory system, or compartment syndrome, and the second is the intrinsic partial or complete occlusion of the extracardiac large vessels, or vena cava syndrome.

The resistance to venous return will be significantly impeded in situations in which pericardial, mediastinal, thoracic or abdominal pressure will increase, such as during an abdominal compartment syndrome. [148;239] In these situations, an upward shift of the pressure-volume curve will be observed. The right and left ventricular pressure will be high (from the outside compression) and volume normal or low (Figure 41).




Figure 41 Mechanism of increased resistance to venous return during tamponade

In tamponade, venous return and cardiac output are reduced. Right atrial pressure is increased. This is secondary to the rise in pericardial pressure. In addition, venous return will now be limited not by subatmospheric pressure but by the pericardial pressure. As a

result, venous return is now equal to the difference between Pms and the pericardial pressure divided by the resistance to venous return. The venous return slope is reduced from an increase in the resistance to venous return. A normal compensatory increase in mean systemic pressure (Pms) will also be observed secondary to the activation of the autonomic nervous system. (B) Biventricular pressure-volume relationships in pericardial tamponade. The increase in pericardial pressure will be transmitted to both ventricles. As a consequence, an upward shift of the horizontal part of the pressure-volume relationship will be observed. This is typically associated with the equalization of end-diastolic pressures. As pericardial pressure increases and tamponade develops, biventricular volumes will be further reduced. Consequently, left ventricular pressure and systemic pressure will be reduced. (With permission of Durand *et al.* [240])

These conditions are difficult to diagnose without echocardiography and extracardiac pressure or intra-abdominal monitoring. [27] However, as the chest and pericardium are opened at the end of cardiac surgery, their contribution to hemodynamic instability is minimal and can be neglected. However, their contribution will appear as soon as the chest is closed. The causes of increased Rvr are pericardial (cardiac tamponade), mediastinal (after CPB), pleural (hemothorax and pneumothorax) and abdominal compartment syndromes.

In the classical presentation of cardiac tamponade, fluid accumulates across the pericardium. The right atrium, having the lowest pressure, will be the first cardiac chamber to collapse in diastole, followed by the right ventricle and left atrium in diastole. This can be easily diagnosed using transthoracic or transesophageal echocardiography (Figure 42).




Figure 42 Classical tamponade.

Classical tamponade diagnosed using transesophageal echocardiography in a patient, developing after surgical coronary revascularization from a deep transgastric view. (A) The arterial pressure (Pa) waveform shows the typical respiratory variation of pulsus paradoxus. The patient was on significant high doses of noradrenaline. (B) The intermittent compression of the right atrium (RA) can be visualized (CABG, coronary artery bypass graft; LV, left ventricle; PE, pericardial effusion). (With permission of Durand *et al.* [240])

After cardiac surgery, however, localized tamponade can occur with the regional compression of any of the cardiac chambers. In such a situation, transesophageal echocardiography is mandatory to rule out regional tamponade (Figure 43). As tamponade progresses and shock worsens, coronary perfusion pressure is compromised, leading to additional myocardial dysfunction. [241]




Figure 43 Regional tamponade.

Transesophageal echocardiography from a mid-esophageal view showing a large clot compressing the right atrium (RA) and right ventricle (RV) before (A,B) and after (C,D) removal . (LA: left atrium, LV: left ventricle) (With permission of Durand *et al.* [240])

The other mechanism of increased Rvr is any pleural pathology that would increase the extrinsic cardiac pressure. This can be a hemothorax or a pneumothorax. The former can be diagnosed using echocardiography (**Erreur ! Source du renvoi introuvable.**); however, the latter is more difficult to diagnose, as ultrasound does not penetrate air. Nevertheless, specific echocardiography signs of pneumothorax have been described using chest ultrasound [242] and could perhaps be used together with transthoracic echocardiography at the bedside. Just as with tamponade, the consequence of the pneumothorax is the compression of the cardiac cavity with the lowest pressure. If the

pneumothorax is anterior to the left side, the RVOT will be compressed specifically during diastole (Figure 44) We observed and reported this condition after lung transplantation. [27]




Figure 44 Hemodynamic consequence of a pneumothorax

A 19-year-old hemodynamically unstable man with chest contusion was admitted for organ donation. Using a mid-esophageal view of the right ventricular outflow tract (RVOT), a diastolic obstruction of the RVOT was observed using M-mode. The obstruction was secondary to an anterior left pneumothorax compressing the RVOT.

In complex and long procedures, it has been noted in some patients that the closure of the sternum produces hemodynamic instability that is reversible when the chest is reopened. The mechanism is secondary to extrinsic compression of the cardiac structures (Figure 45).




Figure 45 Mediastinal tamponade

A 62-year-old woman was admitted for urgent revascularization after failure of coronary angioplasty. She was intubated and on vasoactive agents before the surgery. (A) Her hemodynamic waveforms are shown before. As the chest was closed, she became more hemodynamically unstable with increased vasoactive requirements. This was associated with equalization of the right ventricular and diastolic pulmonary artery pressures (B). In addition, profound bilateral brain desaturation was observed using near-infrared spectroscopy (NIRS) (C). It was then decided to reopen the chest (D) and to transfer the patient to the intensive care unit with a sterile dressing on the mediastinum. The reopening of the chest was associated with an improved hemodynamic condition and improved NIRS values (E).

The last mechanism of extrinsic compression is the abdominal compartment syndrome (ACS) and, unfortunately, it is still poorly recognized and diagnosed in cardiac surgery. Abdominal compartment syndrome is defined as a sustained abdominal pressure > 20 mmHg with evidence of organ dysfunction relieved by abdominal decompression. [239] The term intra-abdominal hypertension (IAH) is used to describe abdominal pressures ranging from 12 to 20 mmHg. An increased pressure in a non-expendable compartment reduces capillary bed perfusion and promotes bacterial translocation, which is then followed by the activation of inflammatory cytokines. [136] The latter causes leakage through vascular walls and edema, which further contributes to the rise in intra-abdominal

pressure. The reduction in the abdominal perfusion pressure (APP) defined as the difference between mean arterial pressure (MAP) and intra-abdominal pressure (IAP) leads to organ ischemia. The associated rise in abdominal pressure increases the resistance to venous return (Figure 41). This will reduce venous return and lead to low cardiac output and shock. [243] Furthermore, as the IAP increases, the diaphragm is pushed cephalad which reduces thoracic or the extrapulmonary compliance. The consequences of this condition include a reduced glomerular filtration, an oligoanuric state, hepatic dysfunction and intestinal ischemia. The acute compartment syndrome has been shown to be an independent risk factor for mortality in the intensive care unit. [244] The risk factors of ACS are summarized in Table 13 and can be divided in three categories: diminished wall compliance, increased intra-abdominal content and capillary leak. [244;245]

From Table 13, it appears that several of these risk factors can be present during cardiac surgery. Clinical manifestations are non-specific and include decreased urine output, high ventilatory pressures and a tense abdomen. Monitoring the intravesical pressure is essential to establishing the diagnosis. In patients with intra-abdominal hypertension and acute compartment syndrome, the abdominal perfusion pressure should be maintained above 50-60 mmHg. [148] Treatment should be directed towards the management of the underlying cause. Specific goals should be to improve abdominal wall compliance, reduce abdominal fluid and/or air and to correct the positive fluid balance. The most definitive intervention is decompression laparotomy with temporary abdominal closure. [246] However, this approach is not without risks and is not always curative. [247] The use of diuretics, paracentesis, nasogastric tubes (Figure 46) and dialysis can be very effective.

Table 13 Abdominal compartment syndrome

1) Diminished wall compliance

- Abdominal surgery
- Acute respiratory distress syndrome
- Major burns/trauma
- Mechanical ventilation
- Prone position
- Obesity (body mass index > 30 kg/m²)

2) Intra-abdominal content

- Liver dysfunction (ascitis)
- Hemo-/pneumoperitoneum
- Increasing intraluminal fluid content (Ex. contrast enema)
- Ileus/gastroparesis
- Acute colonic pseudo-obstruction; colonic dilatation (Ogilvie syndrome)
- Tumor

3) Capillary leak/resuscitation

- Massive resuscitation
- Polytransfusion (> 10 blood units/24 h)
- Acidosis (pH < 7.2)
- Sepsis
- Hypothermia (< 33° C)
- Hypotension
- Coagulopathy
- Major burns/trauma
- Emergency laparotomy

(With permission of Deslauriers *et al.* [158])



Figure 46 Acute abdominal compartment syndrome after induction of anesthesia.

A 65-year-old woman difficult to intubate and ventilate was hemodynamically unstable after the induction of general anesthesia. A chest radiograph demonstrates a distended stomach. A nasogastric tube was inserted and the vasoactive support stopped.

The second mechanism of increased resistance to venous return is the vena cava syndrome, which results in the intrinsic obstruction of the large vessels. In such a situation, a significant hemodynamic instability will be present with a normal or reduced cardiac volume similar to a reduction in Pms. This has been observed following the removal of the inferior vena cava cannula and accidental partial closure of the inferior vena cava (Figure 47). We have seen it also during a Fontan procedure during which the anastomosis to the inferior vena cava was partially obstructed (Figure 48).




Figure 47 Partially occluded inferior vena cava (IVC)

(A,B) Mid-esophageal right ventricular view in a patient after aortic valve replacement. A turbulent flow was observed at the entrance of the IVC. It was secondary to a partial obstruction of the IVC at the site of cannulation. (C) Significantly reduced hepatic venous flow (HVF) with systolic reversal was present.




Figure 48 Inferior vena cava (IVC) occlusion during Fontan procedure

(A,B) Transgastric view showing a dilated IVC following a Fontan procedure. The occlusion was secondary to a partial occlusion at the level of the graft anastomosis to the IVC. (C,D) Hepatic venous flow (HVF) before and after cardiopulmonary bypass (CPB). The HVF is almost absent after CPB.

A misplaced intra-aortic balloon catheter in the inferior vena cava will also contribute to hemodynamic instability, particularly during diastole when it is inflated (Figure 49). All these conditions can be suspected or diagnosed with the use of TEE.




Figure 49 Intra-aortic balloon pump (IABP) catheter in the inferior vena cava (IVC).

(A,B) Emergency positioning of the IABP in the operating room after cardiopulmonary bypass. The IABP was not in the aorta but in the IVC. (With permission of Denault *et al.* [13])

The superior vena cava can also be obstructed during cardiac surgery. Typically, it is caused by a misplaced or obstructing superior vena cava venous cannula. Although this is not typically associated with hemodynamic instability, it can lead to brain hypoperfusion by reducing the cerebral perfusion pressure. Pressure monitoring of the internal jugular pressure and infrared spectroscopy are modalities useful in such diagnoses (Figure 50).

In summary, the resistance to venous return, either through the extrinsic compression of the cardiac chambers or great vessels (compartment syndrome) or through a partial or complete vascular occlusion (vena cava syndrome), is an important factor that needs to be diagnosed during cardiac surgery as a potential mechanism of hemodynamic instability and difficult separation from CPB.




Figure 50 Brain desaturation during cardiac transplantation.

(A) A reduction down to 43% in brain saturation was observed during cardiac transplantation. (B) Despite adequate mean arterial pressure (from radial and femoral transducers) during cardiopulmonary bypass, the desaturation was associated with an increase in the left internal jugular vein (LIJV) pressure of 65 mmHg. At that point, the cardiothoracic surgeon decided to reposition the superior vena cava (SVC) cannula that was occluding cerebral venous return. The brain oximetry value increased. (C) The LIJV pressure decreased to 12 mmHg. (With permission of Denault *et al.* [130])

3.1.4 Combined mechanism

Finally, combinations of causes of difficult separation from CPB are the rule rather than the exception. [19] For instance, RV systolic failure will lead to LV diastolic dysfunction through septal interaction (Figure 27). In these conditions, the hemodynamic values will be the result of two different conditions, and only echocardiography can enable the diagnosis of these two separate entities, as previously shown. [19] Severe shock state independently of their cause, when persisting, can lead to vasodilatory shock. [137]

In our experience, the majority of these diagnoses can be made via the combination of both hemodynamic and echocardiographic modalities. These conditions require a specific treatment. [44] For instance, inotropes are indicated in the presence of left or right ventricular systolic dysfunction, but contra-indicated in the presence of outflow tract obstruction. [38] In both conditions, the hemodynamic characteristics will be the same: reduced venous return and elevated filling pressure. However, the treatment is completely the opposite: inotropic therapy is indicated with systolic dysfunction, but inotropic withdrawal is the therapy for any outflow tract obstruction.

Conditions associated with increased right atrial pressure are particularly important to differentiate using TEE. Each condition has a different therapeutic implication, as shown in Table 14. This is one of the reasons why the use of TEE is considered a type 1 indication in the presence of hemodynamic instability. [248] Echocardiography is therefore an essential tool in any research dealing with complex hemodynamic conditions. A systematic approach in the diagnosis and treatment of hemodynamic instability should be proposed in cardiac surgery. This approach should be based on the concept of venous return and uses combined and simultaneous TEE and hemodynamic monitoring to estimate biventricular pressure volume relationships.

Figure 51 summarizes the mechanisms of hemodynamic instability resulting from reduced Pms, increased Pra and Rvr. Relevant hemodynamic and echocardiographic measurements performed during cardiac surgery are summarized in Table 15.

Table 14 Mechanisms of hemodynamic instability and therapeutic implication

Etiology	Timing	Possible mechanism	Therapeutic implication	Pharmacological treatment of hemodynamic instability after CPB				
				Fluid therapy	Inotropes ¹	Vasodilators ²	Vasopressors ³	Other
LV systolic dysfunction	Before CPB	Coronary artery disease	Coronary revascularization					
		Natural evolution of U/L disease	No indication for revascularization					
	During CPB	Poor myocardial protection?	Retrograde cardioplegia position adequate?					
	After CPB	Air embolism	LV de-airing					
		Coronary ostium obstruction from the prosthesis	Coronary revascularization and LVAD if severe	+	++	+	+	
LV diastolic dysfunction	Before CPB	Coronary artery disease or natural evolution	Coronary revascularization					
	After CPB	Poor myocardial protection?	If associated with new systolic dysfunction, revascularization might be considered	+	-	+/-	+/-	Some benefit from beta-blockade
LV outflow tract obstruction	Before CPB	LV hypertrophy	LV outflow tract enlargement					
	After CPB	LV hypertrophy, edema and inotropes	May lead to return on CPB and MVR if associated with SAM	+	-	-	+	Some benefit from beta-blockade
Pulmonary hypertension	Before CPB	Post-capillary from increased LVEDP	Rule out absence of correctable mitral regurgitation					
	After CPB	Valve dysfunction of pulmonary reperfusion syndrome	Return of CPB if dysfunctional prosthesis	+	+	+	+	Inhaled agents may be considered
RV systolic dysfunction	Before CPB	Coronary artery disease or consequence of PHT						Preemptive inhaled agents may be considered
	After CPB	Poor myocardial protection or consequence of PH	Coronary revascularization and RVAD if severe	+	+	+	+	Inhaled agents may be considered
		Associated with septal shift		-	+	++	++	
RV diastolic dysfunction	Before CPB	Consequence of PH						

Etiology	Timing	Possible mechanism	Therapeutic implication	Pharmacological treatment of hemodynamic instability after CPB				
			Surgical consideration	Fluid therapy	Inotropes ¹	Vasodilators ²	Vasopressors ³	Other
RV outflow tract obstruction	Before CPB	LV septal hypertrophy		+/-	-	+/-	+/-	Treatment of PH may improve
	After CPB	Poor myocardial protection or consequence of PH						
	After CPB	LV hypertrophy, edema and inotropes		+	-	-	+	Some benefit from beta-blockade
Patient-prosthesis mismatch	Before CPB	Small aortic root	Aortic root enlargement, homograft					
	After CPB	Small prosthetic area in relation with body surface area		+	-	-	+/-	Some benefit from beta-blockade

CPB: cardiopulmonary bypass, LV: left ventricle, LVAD: left ventricular assist device, LVEDP: left ventricular end-diastolic pressure, MVR: mitral valve replacement, PH: pulmonary hypertension, RV: right ventricle, RVAD: right ventricular assist device, SAM: systolic anterior motion, U/L: underlying

1 Inotropes: adrenaline, milrinone, isoproterenol, ephedrine

2 Vasodilators: nitroglycerin, nitroprusside, milrinone

3 Vasopressors: phenylephrine, noradrenaline, vasopressin, methylene blue

Inhaled agents specific to pulmonary vessels (inhaled prostacyclin, inhaled milrinone, nitric oxide)

+ Indicated; - Counter-indicated; +/- Benefit is unclear




Figure 51 Mechanism of hemodynamic instability in cardiac surgery

(PPM, patient-prosthesis mismatch)

Table 15 Summary of the hemodynamic and echocardiographic measurements

Etiology	Measurement	Timing			Echocardiographic assessment	
		Before CPB	During CPB	After CPB		
LV systolic dysfunction	LV hypertrophy	X			LVH based on LV mass	
	LV dilatation	X		X	45 mm systole and 55 mm diastole	
	LA dilatation	X		X	Maximum transverse diameter	
	Regional wall motion abnormalities		X		X	1 = normal,
						2 = hypokinetic,
						3 = akinetic,
					4 = dyskinetic	
	Regional wall motion score index	X		X	Total score divided by the number of segments	
	Left ventricular ejection fraction	X		X	Simson's rule using a 2- and 4-chamber view	
	Left ventricular fractional area change	X		X	Transgastric view in diastole and systole	
	Other: air embolism, floating plaques	X		X	Continuous 2D monitoring	
LV diastolic dysfunction					Classified according to an algorithm using:	
	Transmitral flow	X		X	Pulsed-wave Doppler at the tip of mitral valve	
	Pulmonary venous flow	X		X	Pulsed-wave Doppler 1 cm within pulmonary vein	
	Mitral annular velocities	X		X	Tissue Doppler on lateral wall	

Etiology	Measurement	Timing			Echocardiographic assessment
		Before CPB	During CPB	After CPB	
LV outflow tract obstruction	Propagation velocities	X		X	Color M-Mode mid-esophageal 120°
	LV outflow tract measurements	X			Measured in the ME 5 chamber
	Color Doppler in the LVOT	X		X	Color Doppler mid-esophageal 120°
	LV septal wall measurement	X			Mid-esophageal 120°
Pulmonary hypertension	Pressure gradient measurement across the LVOT				Mid-esophageal 120°: normally less than 4 mmHg
	Brockenborough Braunwald phenomenon	X		X	A reduced arterial pressure after a premature ventricular complex is almost pathognomonic
	Using the pulmonary artery catheter	X		X	Mild PHT: PAPS > 30 mmHg, MPAP > 25 mmHg and MAP/MPAP 33-50%
					Severe PHT: SPAP > 50 mmHg, MPAP > 30 mmHg and MAP/MPAP > 50%
RV systolic dysfunction	2D Measurement of the RA and RV	X		X	Mid-esophageal 4-chamber view
	Fractional area change	X		X	Mid-esophageal 4-chamber view
	RV myocardial performance index	X			Using CW across TV valve and deep TG view for ET

Etiology	Measurement	Timing			Echocardiographic assessment
		Before CPB	During CPB	After CPB	
RV diastolic dysfunction	Septal shift	X		X	Eccentricity index will be used
	Tricuspid annular plane systolic excursion	X		X	Measured using anatomic M-mode
					Classified according to an algorithm using:
	Transtricuspid flow	X		X	Pulsed-wave Doppler at the tip of tricuspid valve
	Hepatic venous flow	X		X	Pulsed-wave Doppler 1 cm within hepatic vein
	Tricuspid annular velocities	X		X	Tissue Doppler on inferior wall
RV outflow tract obstruction	Using the paceport of the pulmonary artery catheter	X		X	Dedicated transducer for RV measurement
	2D view of the RV inflow-outflow	X		X	Mid-esophageal 40° to 70° view
	Deep transgastric view of the RV inflow-outflow	X		X	Deep transgastric view
	Measurement of the pressure gradient across the TV	X		X	A pressure gradient superior to the systolic pulmonary artery pressure will be observed
Patient-prosthesis mismatch	Measurement of the aortic annulus	X			Mid-esophageal 120°
	Table consultation of the EOA of the inserted prosthesis	X			Table used to obtain values for each type of valve
	Pressure-gradient across the LVOT	X		X	Deep transgastric view

Etiology	Measurement	Timing			Echocardiographic assessment
		Before CPB	During CPB	After CPB	
Other measurements and observations:	Confirmation of the absence of any paravalvular leaks	X	X	X	Mid-esophageal 120°
	Confirmation of the position of the retrograde cardioplegia		X		Confirm presence in the coronary sinus
	Confirmation of the position of the inferior vena cava cannula		X		Confirm presence in the inferior vena cava
	Confirmation of the position of the aortic cannula	X	X		Confirm adequate position and good flow
	Confirmation of the position of any LVAD, RVAD or IABP		X	X	Confirm adequate position and good flow
	Severity of aortic atheromatosis	X			Classified using grade 1 to 5
	Ruling out aortic dissection	X	X	X	Confirm adequate position and good flow
	Ruling out inferior vena cava obstruction			X	Low-esophageal view 0°
	Ruling out free pleural or peritoneal fluid			X	Mid-esophageal, low-esophageal and transgastric views

Legends: AVR: aortic valve replacement, 2D: two-dimensional, CPB: cardiopulmonary bypass, IABP: intra-aortic balloon pump, LV: left ventricle, LVAD: left ventricular assist device, LVEDP: left ventricular end-diastolic pressure, LVOT: left ventricular outflow tract, ME: mid-esophageal, PHT: pulmonary hypertension, RA: right atrium, RV: right ventricle, RVAD: right ventricular assist device.

3.2 Research and development since the beginning of the PhD in 2006 at the MHI

Several of the determinants of venous return were studied over the last four years. They will be discussed in this section.

3.2.1 Studies on alternative measurement of venous return and cardiac output

Venous return and cardiac output can be measured using several techniques. In the operating room, we commonly use the pulmonary artery catheter to obtain thermodilution-derived cardiac output. In addition, the use of Doppler echocardiography allows us to calculate cardiac output. [12] The limitation of these two methods is that they are invasive and provide intermittent measurements only. An alternative to this technique would be near-infrared spectroscopy (NIRS).

Near-infrared spectroscopy (NIRS) is a technique that was first developed in the 70s [249;250] and that can be used as a non-invasive and continuous monitor of the balance between cerebral oxygen delivery and consumption. [135] Several different specialties such as neurology, [251] neurosurgery, [252] traumatology, [253] vascular surgery, [254] and adult [135] and pediatric cardiac surgery [255] have been using this monitor to measure brain and tissue perfusion. [129] In fact, some randomized controlled trials have recently shown the usefulness of this monitor to predict negative outcomes in non-cardiac [133] and cardiac surgery. [134] Several factors can affect oxygen delivery to the brain such as cardiac output, hemoglobin concentration, arterial oxygen saturation and partial pressure of oxygen. However, in an awake patient, the major determinants of baseline brain oximetric signals are not clearly described. Few studies have reported the relationship between cerebral oximetry values (ScO_2) and cardiac function. [249;250] As cardiac performance is reduced, increased brain oxygen extraction and lower ScO_2 values can be observed. [249] In addition, ScO_2 has been shown to correlate with the presence of left ventricular dysfunction in patients with valvular disease during exercise testing. [250] However, ScO_2 has never been compared with both hemodynamic and echocardiographic assessments of

the cardiac function in patients undergoing cardiac surgery. Our hypothesis was that the baseline mean ScO₂ value measured before surgery is determined by cardiac function and correlates with hemodynamic and echocardiographic parameters.

In order to test our hypothesis, we performed a retrospective analysis of patients undergoing cardiac surgery with bilateral recording of their baseline cerebral brain oxygen saturation (ScO₂) using the INVOS 4100 (Somanetics, Troy, MI, USA). [47] A pulmonary artery catheter was used to obtain their hemodynamic profile. Left ventricular systolic and diastolic function were evaluated by TEE, after induction of anesthesia, using standard criteria. A model was developed to predict ScO₂. A total of 99 patients met the inclusion criteria. There were significant correlations between mean ScO₂ values and central venous pressure (CVP) ($r = -0.31, p = 0.0022$), pulmonary capillary wedge pressure (PCWP) ($r = -0.25, p = 0.0129$), mean pulmonary artery pressure (MPAP) ($r = -0.24, p = 0.0186$), mean arterial pressure/mean pulmonary artery pressure ratio (MAP/MPAP) ($r = 0.33, p = 0.0011$), LV fractional area change (< 35, 35-50, $\geq 50, p = 0.0002$), regional wall motion score index ($r = -0.27, p = 0.0062$) and diastolic function ($p = 0.0060$). Mean ScO₂ presented the highest area under the receiver operating curve (ROC) (0.74; CI 0.64-0.84) to identify LV systolic dysfunction. A model predicting baseline ScO₂ was created based on LV systolic echocardiographic variables, CVP, gender, mitral valve surgery and the use of beta-blocker ($r^2 = 0.42, p < .001$). Baseline ScO₂ values were related to cardiac function and superior to hemodynamic parameters at predicting left ventricular dysfunction. Our observations are summarized in Figure 52.




Figure 52 Brain-heart interaction

Relationship between reduced cerebral oxygen saturation (ScO_2) and cardiac systolic/diastolic function. As systolic cardiac function is reduced through a reduction in the left ventricular fractional area change (FAC) or an increase in the regional wall motion score index (RWMSI), the mean arterial pressure (MAP) will be reduced. Cardiac performance can also result from left ventricular diastolic dysfunction (LVDD), which can be present with or without systolic dysfunction. In this case, the left atrial pressure (LAP), pulmonary capillary wedge pressure (PCWP) and consequently the mean pulmonary arterial pressure (MPAP) will increase, the MAP/MPAP ratio decrease and this may lead to an increase of the central venous pressure (CVP). As the CVP is used to estimate the intracranial pressure, the cerebral perfusion pressure (MAP-CVP) will be reduced. The result will be a reduction in cerebral blood flow (CBF). This will lead to an increase in the oxygen extraction of the brain. This explains why a reduced cardiac function is associated with reduced ScO_2 . (LA: left atrium; LV: left ventricle; RA: right atrium; RV: right ventricle). (With permission of Paquet *et al.* [47])

3.2.2 Studies on causes of increased Pra

Over the last 4 years we performed studies on systolic and diastolic dysfunction and documented the prevalence of RVOTO.

3.2.2.1 Left ventricular systolic and diastolic function

To support our hypothesis on the role of left ventricular systolic dysfunction as a predictor of outcome in cardiac surgery, we performed an observational study that included 3024 adult patients who underwent cardiac operations at the Montreal Heart Institute (MHI) from 1996 to 2000 (61% of the population operated in that period) and in whom left ventricular ejection fraction and other variables were measured prior to the cardiac surgery. [11] Left ventricular ejection fraction was the last measured value reported prior to surgery by left ventriculography, [256] echocardiography [257] or nuclear medicine. [258] The lowest value was selected. Surgical procedures were categorized as coronary revascularization, valvular, complex valve, re-operations and various. The complex operations were either multivalvular or valvular with or without coronary revascularization. Include also were ascending thoracic aorta operation and surgery for complications of myocardial infarction. Off-pump cardiac surgery and surgery of the descending aorta or patent ductus arteriosus were excluded. The primary outcome in this study was hospital mortality. Patients undergoing coronary revascularization were further stratified according to abnormal LV. Those left ventricular ejection fraction values were based on previous studies which identified them as cut-offs associated with increased mortality and morbidity. [8;100;259] Only variables with p values < 0.25 in univariate analysis were considered potential predictors of the primary outcome for multivariate analysis. Variable clustering was employed to further reduce the number of redundant variables before building a multivariate model. Then, stepwise multiple logistic regression analysis was undertaken to determine the independent predictors of death. P values < 0.05 were considered to be statistically significant. A total of 3024 patients were taken into account in the study. There were 99 deaths (3.3%). Of the 35 variables subjected to univariate analysis, 23 demonstrated a significant association with the occurrence of death. Stepwise

multiple logistic regressions identified eight variables to be independent predictors of death after cardiac surgery. These included age, weight, hypertension, treated diabetes, reoperation, left ventricular end-diastolic pressure, left ventricular ejection fraction and duration of CPB. Therefore, for a relative reduction of 10% of left ventricular ejection fraction, the risk of death increases by 32% (14-53%). A total 57% of deaths were attributed to hemodynamic instability. Postoperatively, 6% of those who died required vasopressors and 17% required an intra-aortic balloon pump (IABP) to be weaned, compared with 1% and 4% in the survivors group, respectively ($p < 0.0001$).

As mentioned previously, Salem *et al.* conducted an observational study to determine the relationship between preoperative left ventricular end-diastolic pressure and mortality following cardiac surgery. [11] The hypothesis was that an elevated left ventricular end-diastolic pressure, with or without preserved left ventricular systolic function, is associated with a poor outcome after cardiac surgery. As shown in Table 16, left ventricular end-diastolic pressure was found to be an independent predictor of mortality. For a relative increase in 5 mmHg of left ventricular end-diastolic pressure, the risk of mortality increases by 19% (5-35%).

Table 16 Multivariate analysis for mortality

Predictors	P	Units	Odds ratio	95% CI
Age	< 0.0001	20	4.255	2.461, 7.355
Weight, kg	0.0403	-10	1.190	1.008, 1.404
LVEDP	0.0062	5	1.195	1.052, 1.357
LVEF	0.0002	-10	1.326	1.145, 1.535
CPB length, min	< 0.0001	30	1.813	1.608, 2.044
Reoperation	< 0.0001	--	2.669	1.636, 4.354
Hypertension	0.0211	--	1.687	1.082, 2.632
Treated diabetes	0.0277	--	1.759	1.064, 2.906

CI indicates confidence interval; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction; CPB, cardiopulmonary bypass. (From Salem *et al.* [11])

Furthermore, in patients undergoing coronary revascularization ($n = 2445$), the mortality in patients with left ventricular ejection fraction < 30% was higher in those with elevated left ventricular end-diastolic pressure > 19 mmHg (12%) compared to those with left ventricular end-diastolic pressure \leq 19 mmHg (0%) (Table 17).

Table 17 Mortality in patients undergoing coronary artery bypass grafting

	LVEDP > 19mmHg LVEF < 30%	LVEDP > 19mmHg LVEF > 30%	LVEDP \leq 19mmHg LVEF < 30%	LVEDP \leq 19mmHg LVEF > 30%
No	75 (88%)	1244 (97%)	30 (100%)	1033 (98%)
Yes	10 (12%)*	35 (3%)	0 (0%)	18 (2%)
Total	85	1279	30	1051

LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction * $P < 0.0001$ compared with patients with LVEDP \leq 19 and LVEF < 30 (From Salem *et al.* [11])

A similar trend was observed in non-coronary revascularization patients ($n = 895$), but it was not statistically significant (Table 18). The definition of diastolic dysfunction can be applied to patients with or without LV systolic dysfunction who have filling abnormalities. In summary, these observations support the link between mortality and both left ventricular systolic and diastolic dysfunction.

Table 18 Mortality in patients undergoing non-coronary artery bypass grafting

	LVEDP \geq 19mmHg LVEF \leq 30%	LVEDP \geq 19mmHg LVEF \geq 30%	LVEDP \leq 19mmHg LVEF \leq 30%	LVEDP \leq 19mmHg LVEF \geq 30%
No	41 (89%)	292 (94%)	26 (93%)	480 (96%)
Yes	5 (11%)	19 (6%)	2 (7%)	20 (4%)
Total	46	311	28	500

LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction. (From Salem *et al.* [11])

3.2.2.2 Right ventricular systolic and diastolic function

To further assess the value of right ventricular function in relation to other validated risk factors in open valvular heart surgery, we published our experience with 50 consecutive patients undergoing valvular surgery. [46] In our study we confirmed that, in patients with a right ventricular myocardial performance index (RVMPI) above 50% ($n = 20$), the number of patients with difficult separation from CPB (16/20 (80%) vs. 6/30 (20%), $p < 0.0001$) and the endpoint of mortality of postoperative heart failure (14/20 (74%) vs. 3/30 (10%), $p < 0.0001$) were significantly higher. On a multivariate analysis, among all other demographic, hemodynamic and echocardiographic variables, the RVMPI was the only independent predictor of heart failure and mortality (OR: 25.20, 95% CI 5.24-121.15, $p < 0.0001$).

3.2.2.3 Right ventricular outflow tract obstruction

The prevalence of RVOTO was retrospectively studied in 670 consecutive patients undergoing cardiac surgery. [38] Significant RVOTO was diagnosed if the right ventricular systolic to pulmonary artery peak gradient was over 25 mmHg. The diagnosis was based on the measurement of the right ventricular and pulmonary artery systolic pressures through the papeport and distal opening of the pulmonary artery catheter. To further validate the prevalence and the importance of RVOTO, 130 patients were prospectively studied over a 12-month period. In the retrospective cohort, 6 patients (1%) undergoing various types of cardiac surgical procedures were found to have significant dynamic obstruction with a mean gradient of 31 ± 4 mmHg (26 to 35 mmHg). In the prospective study, significant dynamic obstruction was identified in 5 patients (4%) (average peak: 37 ± 15 mmHg; range: 27 to 60 mmHg). The typical transesophageal echocardiography finding was end-systolic obliteration of the RVOT (Figure 53).




Figure 53 Dynamic right ventricular outflow tract (RVOT) obstruction

Septal myomectomy and aortic surgery in a 68-year-old man complicated by dynamic RVOT obstruction appearing during weaning from cardiopulmonary bypass. (A) The systolic gradient between the right ventricle and the pulmonary artery was 28 mmHg. (B,C,D) M-mode view from a mid-oesophageal right ventricular inflow-outflow view at 63°. Note the dynamic obstruction of the right ventricular outflow in systole in this (LA, left atrium; Pa, arterial pressure; Ppa, pulmonary artery pressure; Prv, right ventricular pressure; RA, right atrium; RV, right ventricle). (With permission of Denault *et al.* [38])

In patients with significant dynamic RVOTO, hemodynamic instability was present in 10/11 patients (91%). Therefore, RVOTO is easily diagnosed using the papeport of the pulmonary artery catheter (Figure 54) and should be considered a potential cause of hemodynamic instability, especially when TEE shows systolic right ventricular cavity obliteration.




Figure 54 Hemodynamic and Doppler findings in dynamic RVOT obstruction

A 68-year-old man underwent aortic valve replacement. He became hemodynamically unstable with right ventricular dysfunction and was put back on cardiopulmonary bypass. Inotropes were initiated. On the second weaning attempt, he developed severe right ventricular outflow tract (RVOT) obstruction confirmed with the papeport of the pulmonary artery catheter and through continuous-wave Doppler interrogation of the tricuspid regurgitant flow in a mid-oesophageal ventricular inflow-outflow view at 61°. The measured pressure gradient of the tricuspid regurgitant flow was 75 mmHg (with a right ventricular systolic pressure of 80 mmHg) and the pulmonary artery pressure (Ppa) was 30/16 mmHg during the echocardiographic measurement. (EKG, electrocardiogram; Pa, arterial pressure; Prv, right ventricular pressure). (With permission of Denault *et al.* [38])

In summary, the mechanism of hemodynamic instability is complex but can be understood through a specific approach based on hemodynamic and echocardiographic variables. Therefore, such measures are essential to the evaluation of hemodynamic instability in cardiac surgery. So far, no studies have measured hemodynamic and echocardiographic variables in consecutive patients undergoing valvular surgery and determined the mechanism of difficult separation from CPB. The mechanism of difficult separation from CPB is important to understand if the next step is to prevent it.

Bibliography

References

1. Herbertson M. Recombinant activated factor VII in cardiac surgery. *Blood Coagul.Fibrinolysis* 2004; 15 Suppl 1: S31-S32.
2. Aronow WS. Heart disease and aging. *Med.Clin.North Am.* 2006; 90: 849-62.
3. Reichert CL, Visser CA, van den Brink RB, Koolen JJ, van Wezel HB, Moulijn AC, Dunning AJ. Prognostic value of biventricular function in hypotensive patients after cardiac surgery as assessed by transesophageal echocardiography. *J.Cardi thorac Vasc Anesth* 1992; 6: 429-32.
4. Davila-Roman VG, Waggoner AD, Hopkins WE, Barzilai B. Right ventricular dysfunction in low output syndrome after cardiac operations: assessment by transesophageal echocardiography. *Ann.Thorac.Surg.* 1995; 60: 1081-6.
5. Kaul TK, Fields BL. Postoperative acute refractory right ventricular failure: incidence, pathogenesis, management and prognosis. *Cardiovasc.Surg.* 2000; 8: 1-9.
6. Ochiai Y, McCarthy PM, Smedira NG, Banbury MK, Navia JL, Feng J, Hsu AP, Yeager ML, Buda T, Hoercher KJ, Howard MW, Takagaki M, Doi K, Fukamachi K. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. *Circulation* 2002; 106: I198-I202.
7. Moazami N, Pasque MK, Moon MR, Herren RL, Bailey MS, Lawton JS, Damiano RJ, Jr. Mechanical support for isolated right ventricular failure in patients after cardiectomy. *J.Heart Lung Transplant.* 2004; 23: 1371-5.
8. Tremblay NA, Hardy JF, Perrault J, Carrier M. A simple classification of the risk in cardiac surgery: the first decade. *Can.J.Anaesth.* 1993; 40: 103-11.
9. Demers P, Elkouri S, Martineau R, Couturier A, Cartier R. Outcome with high blood lactate levels during cardiopulmonary bypass in adult cardiac operation. *Ann.Thorac.Surg.* 2000; 70: 2082-6.
10. Robitaille A, Denault AY, Couture P, Belisle S, Fortier A, Guertin MC, Carrier M, Martineau R. Importance of relative pulmonary hypertension in cardiac

surgery: the mean systemic-to-pulmonary artery pressure ratio. *Journal of cardiothoracic and vascular anesthesia* 2006; 20: 331-9.

11. Salem R, Denault AY, Couture P, Belisle S, Fortier A, Guertin MC, Carrier M, Martineau R. Left ventricular end-diastolic pressure is a predictor of mortality in cardiac surgery independently of left ventricular ejection fraction. *Br.J.Anaesth.* 2006; 97: 292-7.
12. Denault AY, Couture P, Tardif JC, Buithieu J. *Transesophageal Echocardiography Multimedia Manual: A Perioperative Transdisciplinary Approach.* Marcel Dekker, 2005.
13. Denault AY, Couture P, Vegas A, Buithieu J, Tardif JC. *Transesophageal Echocardiography Multimedia Manual, Second edition: A Perioperative Transdisciplinary Approach.* New York: Informa Healthcare (In press), 2010.
14. Girard F, Couture P, Boudreault D, Normandin L, Denault A, Girard D. Estimation of the pulmonary capillary wedge pressure from transesophageal pulsed Doppler echocardiography of pulmonary venous flow: influence of the respiratory cycle during mechanical ventilation. *Journal of cardiothoracic and vascular anesthesia* 1998; 12: 16-21.
15. Couture P, Denault AY, Carignan S, Boudreault D, Babin D, Ruel M. Intraoperative detection of segmental wall motion abnormalities with transesophageal echocardiography. *Can.J.Anaesth.* 1999; 46: 827-31.
16. Couture P, Denault AY, McKenty S, Boudreault D, Plante F, Perron R, Babin D, Normandin L, Poirier N. Impact of routine use of intraoperative transesophageal echocardiography during cardiac surgery. *Can.J.Anaesth.* 2000; 47: 20-6.
17. Bernard F, Denault AY, Babin D, Goyer C, Couture P, Couturier A, Buithieu J. Diastolic dysfunction is predictive of difficult weaning from cardiopulmonary bypass. *Anesth.Analg.* 2001; 92: 291-8.
18. Hache M, Denault AY, Belisle S, Couture P, Babin D, Tetrault F, Guimond JG. Inhaled prostacyclin (PGI₂) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit. *Can.J.Anaesth.* 2001; 48: 924-9.
19. Costachescu T, Denault AY, Guimond JG, Couture P, Carignan S, Sheridan P, Hellou G, Blair L, Normandin L, Babin D, Allard M, Harel F, Buithieu J. The hemodynamically unstable patient in the intensive care unit: hemodynamic vs. transesophageal echocardiographic monitoring. *Crit Care Med.* 2002; 30: 1214-23.

20. Arcand G, Denault AY, Belisle S, Tremblay N, Blain R, Couture P, Sheridan P, Sahab P, Searle N, Taillefer J. The appropriateness of the pulmonary artery catheter in cardiovascular surgery. *Can.J.Anaesth.* 2002; 49: 1001-2.
21. Couture P, Denault AY, Limoges P, Sheridan P, Babin D, Cartier R. Mechanisms of hemodynamic changes during off-pump coronary artery bypass surgery. *Can.J.Anaesth.* 2002; 49: 835-49.
22. Taillefer J, Couture P, Sheridan P, Girard A, Babin D, Denault AY. A comprehensive strategy to avoid transesophageal echocardiography probe damage. *Can.J.Anaesth.* 2002; 49: 500-2.
23. Do QB, Goyer C, Chavanon O, Couture P, Denault AY, Cartier R. Hemodynamic changes during off-pump CABG surgery. *Eur.J.Cardiothorac.Surg.* 2002; 21: 385-90.
24. Lattik R, Couture P, Denault AY, Carrier M, Harel F, Taillefer J, Tardif JC. Mitral Doppler indices are superior to two-dimensional echocardiographic and hemodynamic variables in predicting responsiveness of cardiac output to a rapid intravenous infusion of colloid. *Anesth.Analg.* 2002; 94: 1092-9.
25. Denault AY, Couture P, McKenty S, Boudreault D, Plante F, Perron R, Babin D, Buithieu J. Perioperative use of transesophageal echocardiography by anesthesiologists: impact in noncardiac surgery and in the intensive care unit. *Can.J.Anaesth.* 2002; 49: 287-93.
26. Hache M, Denault AY, Belisle S, Robitaille D, Couture P, Sheridan P, Pellerin M, Babin D, Noel N, Guertin MC, Martineau R, Dupuis J. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery. *J.Thorac.Cardiovasc.Surg.* 2003; 125: 642-9.
27. Denault AY, Ferraro P, Couture P, Boudreault D, Babin D, Poirier C, Buithieu J. Transesophageal echocardiography monitoring in the intensive care department: the management of hemodynamic instability secondary to thoracic tamponade after single lung transplantation. *J.Am.Soc.Echocardiogr.* 2003; 16: 688-92.
28. Martineau A, Arcand G, Couture P, Babin D, Perreault LP, Denault AY. Transesophageal echocardiographic diagnosis of carbon dioxide embolism during minimally invasive saphenous vein harvesting and treatment with inhaled epoprostenol. *Anesth.Analg.* 2003; 96: 962-4, table.
29. Beique FA, Denault AY, Martineau A, Amir I, Cote D, Courval JF, Couture P, Hickey D, Goyer C, Mayrand D, Mistry B, Robinson R, Sheridan P, Sidhu S, Tremblay N, Villeneuve J. Expert consensus for training in perioperative echocardiography in the province of Quebec. *Can.J.Anaesth.* 2003; 50: 699-706.

30. Couture P, Denault AY, Sheridan P, Williams S, Cartier R. Partial inferior vena cava snaring to control ischemic left ventricular dysfunction. *Can.J.Anaesth.* 2003; 50: 404-10.
31. Denault AY, Couture P, Perrault LP, Tardif JC. Diagnosis, predictors, mechanisms and treatment of hemodynamic instability in cardiac surgery: Research perspective at the Montreal Heart Institute . In: *Transworld Research Network*, 2003; 25-43.
32. Denault AY, Couture P, Pellerin M. Images in anesthesia: 3D systolic anterior motion of the mitral valve. *Can.J.Anaesth.* 2004; 51: 481.
33. Bouchard MJ, Denault AY, Couture P, Guertin MC, Babin D, Ouellet P, Carrier M, Tardif JC. Poor correlation between hemodynamic and echocardiographic indexes of left ventricular performance in the operating room and intensive care unit. *Crit Care Med.* 2004; 32: 644-8.
34. Carricart M, Denault AY, Couture P, Limoges P, Babin D, Levesque S, Fortier A, Pellerin M, Tardif JC, Buithieu J. Incidence and significance of abnormal hepatic venous Doppler flow velocities before cardiac surgery. *Journal of cardiothoracic and vascular anesthesia* 2005; 19: 751-8.
35. Chagnon PM, Denault AY, Couture P, Levesque S, Tardif JC, Carrier M. Comparison between "swan-ganz" derived and echocardiographic variables in the prediction of hemodynamic complications following cardiac surgery. *Chest* 2005; 128: 269S-70S.
36. Denault AY, Qizilbash B, Couture P, Cartier R. Transesophageal echocardiography and aortic valve surgery. *Can.J Anaesth.* 2005; 52: A19.
37. Gisbert A, Souliere V, Denault AY, Bouchard D, Couture P, Pellerin M, Carrier M, Levesque S, Ducharme A, Basmadjian AJ. Dynamic quantitative echocardiographic evaluation of mitral regurgitation in the operating department. *J Am.Soc.Echocardiogr.* 2006; 19: 140-6.
38. Denault AY, Chaput M, Couture P, Hebert Y, Haddad F, Tardif JC. Dynamic right ventricular outflow tract obstruction in cardiac surgery. *J Thorac.Cardiovasc.Surg.* 2006; 132: 43-9.
39. Denault AY, Couture P, Buithieu J, Haddad F, Carrier M, Babin D, Levesque S, Tardif JC. Left and right ventricular diastolic dysfunction as predictors of difficult separation from cardiopulmonary bypass. *Can.J.Anaesth.* 2006; 53: 1020-9.

40. Shi Y, Denault AY, Couture P, Butnaru A, Carrier M, Tardif JC. Biventricular diastolic filling patterns after coronary artery bypass graft surgery. *J.Thorac.Cardiovasc.Surg.* 2006; 131: 1080-6.
41. Denault AY, Lamarche Y, Couture P, Haddad F, Lambert J, Tardif JC, Perrault LP. Inhaled milrinone: a new alternative in cardiac surgery? *Semin.Cardiothorac.Vasc.Anesth.* 2006; 10: 346-60.
42. Denault AY, Couture P, Tardif JC, Perrault LP. Hypertension pulmonaire et chirurgie cardiaque. *Cardiologie Contemporaine* 2006; 3: 6-8.
43. Couture P, Denault AY, Pellerin M, Tardif JC. Milrinone enhances systolic, but not diastolic function during coronary artery bypass grafting surgery. *Can.J Anaesth.* 2007; 54: 509-22.
44. Denault AY, Couture P, Rochon A, Bouchard D. Échocardiographie transesophagienne au bloc opératoire. Conf,rences d'acualisation du CongrŠs national d'anesth,sie et de r,animation 2007; 1-16.
45. Qizilbash B, Couture P, Denault AY. Impact of perioperative transesophageal echocardiography in aortic valve replacement. *Semin Cardiothorac Vasc Anesth* 2007; 11: 288-300.
46. Haddad F, Denault AY, Couture P, Cartier R, Pellerin M, Levesque S, Lambert J, Tardif JC. Right ventricular myocardial performance index predicts perioperative mortality or circulatory failure in high-risk valvular surgery. *J Am.Soc.Echocardiogr.* 2007; 20: 1065-72.
47. Paquet C, Deschamps A, Denault AY, Couture P, Carrier M, Babin D, Levesque S, Piquette D, Lambert J, Tardif JC. Baseline regional cerebral oxygen saturation correlates with left ventricular systolic and diastolic function. *Journal of cardiothoracic and vascular anesthesia* 2008; 22: 840-6.
48. Haddad F, Couture P, Tousignant C, Denault AY. The right ventricle in cardiac surgery, a perioperative perspective: I. Anatomy, physiology, and assessment. *Anesth Analg.* 2009; 108: 407-21.
49. Haddad F, Couture P, Tousignant C, Denault AY. The right ventricle in cardiac surgery, a perioperative perspective: II. Pathophysiology, clinical importance, and management. *Anesth Analg.* 2009; 108: 422-33.
50. Couture P, Denault AY, Shi Y, Deschamps A, Cossette M, Pellerin M, Tardif JC. Effects of anesthetic induction in patients with diastolic dysfunction. *Can.J Anaesth.* 2009; 56: 357-65.

51. Denault AY, Bussi eres J, Carrier M, Mathieu P, and the DSB Study Group. The importance of difficult separation from cardiopulmonary bypass: the Montreal and Quebec Heart Institute experience. *Exp Clin Cardiol* 2006; 11 : 37.
52. Piquette D, Deschamps A, Belisle S, Pellerin M, Levesque S, Tardif JC, Denault AY. Effect of intravenous nitroglycerin on cerebral saturation in high-risk cardiac surgery: [L'effet de la nitroglycerine intraveineuse sur la saturation cerebrale dans les chirurgies cardiaques a haut risque]. *Can.J Anaesth.* 2007; 54: 718-27.
53. Lamarche Y, Perrault LP, Maltais S, Tetreault K, Lambert J, Denault AY. Preliminary experience with inhaled milrinone in cardiac surgery. *Eur.J Cardiothorac Surg.* 2007; 31: 1081-7.
54. Guyton AC, Lindsey AW, Bernathy B, Richardson T. Venous return at various right atrial pressures and the normal venous return curve. *Am.J.Physiol* 1957; 189: 609-15.
55. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussieres JS, Cote D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. *N.Engl.J.Med.* 2008; 358: 2319-31.
56. Beaulieu Y, Denault AY, Couture P, Roy D, Talajic M, O'Meara E, Carrier M, Page P, Levesque S, Lambert J, Tardif JC. Perioperative intravenous amiodarone does not reduce the burden of atrial fibrillation in patients undergoing cardiac valvular surgery. *Anesthesiology* 2010; 112: 1-9.
57. Eltzschig HK, Rosenberger P, Loffler M, Fox JA, Aranki SF, Sherman SK. Impact of intraoperative transesophageal echocardiography on surgical decisions in 12,566 patients undergoing cardiac surgery. *Ann.Thorac.Surg.* 2008; 85: 845-52.
58. Royster RL, Butterworth JF, Prough DS, Johnston WE, Thomas JL, Hogan PE, Case LD, Gravlee GP. Preoperative and intraoperative predictors of inotropic support and long-term outcome in patients having coronary artery bypass grafting. *Anesth Analg.* 1991; 72: 729-36.
59. Boldt J, Kling D, Moosdorf R, Hempelmann G. Enoximone treatment of impaired myocardial function during cardiac surgery: combined effects with epinephrine. *J Cardiothorac Anesth* 1990; 4: 462-8.
60. Hardy JF, Searle N, Roy M, Perrault J. Amrinone, in combination with norepinephrine, is an effective first-line drug for difficult separation from cardiopulmonary bypass. *Can.J.Anaesth.* 1993; 40: 495-501.

61. Hardy JF, Belisle S. Inotropic support of the heart that fails to successfully wean from cardiopulmonary bypass: the Montreal Heart Institute experience. *J.Cardiothorac.Vasc.Anesth.* 1993; 7: 33-9.
62. Butterworth JF, Royster RL, Prielipp RC, Lawless ST, Wallenhaupt SL. Amrinone in cardiac surgical patients with left-ventricular dysfunction. A prospective, randomized placebo-controlled trial. *Chest* 1993; 104: 1660-7.
63. De Hert SG, Moens MM, Jorens PG, Delrue GL, DePaep RJ, Vermeyen KM. Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. *Journal of cardiothoracic and vascular anesthesia* 1995; 9: 264-71.
64. Butterworth JF, Legault C, Royster RL, Hammon JW, Jr. Factors that predict the use of positive inotropic drug support after cardiac valve surgery. *Anesth Analg.* 1998; 86: 461-7.
65. Kikura M, Levy JH, Bailey JM, Shanewise JS, Michelsen LG, Sadel SM. A bolus dose of 1.5 mg/kg amrinone effectively improves low cardiac output state following separation from cardiopulmonary bypass in cardiac surgical patients. *Acta Anaesthesiol.Scand.* 1998; 42: 825-33.
66. Yamada T, Takeda J, Katori N, Tsuzaki K, Ochiai R. Hemodynamic effects of milrinone during weaning from cardiopulmonary bypass: comparison of patients with a low and high prebypass cardiac index. *J.Cardiothorac.Vasc.Anesth.* 2000; 14: 367-73.
67. Suematsu Y, Sato H, Ohtsuka T, Kotsuka Y, Araki S, Takamoto S. Predictive risk factors for delayed extubation in patients undergoing coronary artery bypass grafting. *Heart Vessels* 2000; 15: 214-20.
68. van der Maaten JM, De Vries AJ, Henning RH, Epema AH, van den Berg MP, Lip H. Effects of preoperative treatment with diltiazem on diastolic ventricular function after coronary artery bypass graft surgery. *J.Cardiothorac Vasc Anesth* 2001; 15: 710-6.
69. Muller M, Junger A, Brau M, Kwapisz MM, Schindler E, Akinturk H, Benson M, Hempelmann G. Incidence and risk calculation of inotropic support in patients undergoing cardiac surgery with cardiopulmonary bypass using an automated anaesthesia record-keeping system. *Br.J Anaesth.* 2002; 89: 398-404.
70. Groban L, Butterworth J, Legault C, Rogers AT, Kon ND, Hammon JW. Intraoperative insulin therapy does not reduce the need for inotropic or antiarrhythmic therapy after cardiopulmonary bypass. *Journal of cardiothoracic and vascular anesthesia* 2002; 16: 405-12.

71. Wagner F, Yeter R, Bisson S, Siniawski H, Hetzer R. Beneficial hemodynamic and renal effects of intravenous enalaprilat following coronary artery bypass surgery complicated by left ventricular dysfunction. *Crit Care Med.* 2003; 31: 1421-8.
72. Tsukui H, Koh E, Yokoyama S, Ogawa M. Which patients can be weaned from inotropic support within 24 hours after cardiac surgery? *Heart Vessels* 2004; 19: 225-9.
73. McKinlay KH, Schinderle DB, Swaminathan M, Podgoreanu MV, Milano CA, Messier RH, El Moalem H, Newman MF, Clements FM, Mathew JP. Predictors of inotrope use during separation from cardiopulmonary bypass. *Journal of cardiothoracic and vascular anesthesia* 2004; 18: 404-8.
74. Surgenor SD, O'Connor GT, Lahey SJ, Quinn R, Charlesworth DC, Dacey LJ, Clough RA, Leavitt BJ, Defoe GR, Fillinger M, Nugent WC. Predicting the risk of death from heart failure after coronary artery bypass graft surgery. *Anesth Analg.* 2001; 92: 596-601.
75. Rao V, Ivanov J, Weisel RD, Ikonomidis JS, Christakis GT, David TE. Predictors of low cardiac output syndrome after coronary artery bypass. *J.Thorac.Cardiovasc.Surg.* 1996; 112: 38-51.
76. Rao V, Ivanov J, Weisel RD, Cohen G, Borger MA, Mickle DA. Lactate release during reperfusion predicts low cardiac output syndrome after coronary bypass surgery. *Ann.Thorac.Surg.* 2001; 71: 1925-30.
77. Maganti MD, Rao V, Borger MA, Ivanov J, David TE. Predictors of low cardiac output syndrome after isolated aortic valve surgery. *Circulation* 2005; 112: I448-I452.
78. Surgenor SD, Defoe GR, Fillinger MP, Likosky DS, Groom RC, Clark C, Helm RE, Kramer RS, Leavitt BJ, Klemperer JD, Krumholz CF, Westbrook BM, Galatis DJ, Frumiento C, Ross CS, Olmstead EM, O'Connor GT. Intraoperative red blood cell transfusion during coronary artery bypass graft surgery increases the risk of postoperative low-output heart failure. *Circulation* 2006; 114: I43-I48.
79. Dorman T, Breslow MJ, Lipsett PA, Rosenberg JM, Balsler JR, Almog Y, Rosenfeld BA. Radial artery pressure monitoring underestimates central arterial pressure during vasopressor therapy in critically ill surgical patients. *Crit Care Med.* 1998; 26: 1646-9.
80. Denault A, Deschamps A. Abnormal aortic-to-radial arterial pressure gradients resulting in misdiagnosis of hemodynamic instability. *Can.J Anaesth.* 2009.

81. Mohr R, Lavee J, Goor DA. Inaccuracy of radial artery pressure measurement after cardiac operations. *J Thorac.Cardiovasc.Surg.* 1987; 94: 286-90.
82. Thrush DN, Steighner ML, Rasanen J, Vijayanagar R. Blood pressure after cardiopulmonary bypass: which technique is accurate? *Journal of cardiothoracic and vascular anesthesia* 1994; 8: 269-72.
83. Guyton AC. *Textbook of medical physiology.* 6th edn. Philadelphia: Saunders, 1981.
84. Wehlage DR, Bohrer H, Ruffmann K. Impairment of left ventricular diastolic function during coronary artery bypass grafting. *Anaesthesia* 1990; 45: 549-51.
85. Natsuaki M, Itoh T, Ohteki H, Minato N, Ishii K, Suda H. Evaluation of left ventricular early diastolic function after coronary artery bypass grafting relating to myocardial damage. *Jpn.Circ.J* 1991; 55: 117-24.
86. Gorcsan J, III, Diana P, Lee J, Katz WE, Hattler BG. Reversible diastolic dysfunction after successful coronary artery bypass surgery. Assessment by transesophageal Doppler echocardiography. *Chest* 1994; 106: 1364-9.
87. Higashita R, Sugawara M, Kondoh Y, Kawai Y, Mitsui K, Ohki S, Tange S, Ichikawa S, Suma K. Changes in diastolic regional stiffness of the left ventricle before and after coronary artery bypass grafting. *Heart Vessels* 1996; 11: 145-51.
88. Houltz E, Hellstrom A, Ricksten SE, Wikh R, Caidahl K. Early effects of coronary artery bypass surgery and cold cardioplegic ischemia on left ventricular diastolic function: evaluation by computer-assisted transesophageal echocardiography. *J.Cardiothorac Vasc Anesth* 1996; 10: 728-33.
89. De Hert SG, Rodrigus IE, Haenen LR, De Mulder PA, Gillebert TC. Recovery of systolic and diastolic left ventricular function early after cardiopulmonary bypass. *Anesthesiology* 1996; 85: 1063-75.
90. Oppizzi M, Zoia E, Franco A, Gerli C, Vendrame G, Guarracino F, Marino G, Paolillo G. [Diastolic dysfunction in cardiac surgery intensive care. Study methods, changes and prognosis]. *Minerva Anestesiol.* 1997; 63: 29-38.
91. Casthely PA, Shah C, Mekhjian H, Swistel D, Yoganathan T, Komer C, Miguelino RA, Rosales R. Left ventricular diastolic function after coronary artery bypass grafting: a correlative study with three different myocardial protection techniques. *J Thorac.Cardiovasc.Surg.* 1997; 114: 254-60.
92. Diller GP, Wasan BS, Kyriacou A, Patel N, Casula RP, Athanasiou T, Francis DP, Mayet J. Effect of coronary artery bypass surgery on myocardial function as

- assessed by tissue Doppler echocardiography. *Eur.J Cardiothorac.Surg.* 2008; 34: 995-9.
93. Reichert CL, Visser CA, Koolen JJ, vd Brink RB, van Wezel HB, Meyne NG, Dunning AJ. Transesophageal echocardiography in hypotensive patients after cardiac operations. Comparison with hemodynamic parameters. *J Thorac.Cardiovasc.Surg.* 1992; 104: 321-6.
 94. Carroll JD, Hess OM, Hirzel HO, Turina M, Krayenbuehl HP. Left ventricular systolic and diastolic function in coronary artery disease: effects of revascularization on exercise-induced ischemia. *Circulation* 1985; 72: 119-29.
 95. Lawson WE, Seifert F, Anagnostopoulos C, Hills DJ, Swinford RD, Cohn PF. Effect of coronary artery bypass grafting on left ventricular diastolic function. *Am.J.Cardiol.* 1988; 61: 283-7.
 96. Djaiani GN, McCreath BJ, Ti LK, Mackensen BG, Podgoreanu M, Phillips-Bute B, Mathew JP. Mitral flow propagation velocity identifies patients with abnormal diastolic function during coronary artery bypass graft surgery. *Anesth Analg.* 2002; 95: 524-30.
 97. Ekery DL, Davidoff R, Orlandi QG, Apstein CS, Hesselvik JF, Shemin RJ, Shapira OM. Imaging and diagnostic testing: diastolic dysfunction after coronary artery bypass grafting: a frequent finding of clinical significance not influenced by intravenous calcium. *Am.Heart J.* 2003; 145: 896-902.
 98. Skarvan K, Filipovic M, Wang J, Brett W, Seeberger M. Use of myocardial tissue Doppler imaging for intraoperative monitoring of left ventricular function. *Br.J.Anaesth.* 2003; 91: 473-80.
 99. Sakr Y, Reinhart K, Vincent JL, Sprung CL, Moreno R, Ranieri VM, De Backer D, Payen D. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. *Crit Care Med.* 2006; 34: 589-97.
 100. Bernstein AD, Parsonnet V. Bedside estimation of risk as an aid for decision-making in cardiac surgery. *Ann.Thorac.Surg.* 2000; 69: 823-8.
 101. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor PP, Salamon R, Thulin L. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. *Eur.J.Cardiothorac.Surg.* 1999; 15: 816-22.

102. Dupuis JY, Wang F, Nathan H, Lam M, Grimes S, Bourke M. The cardiac anesthesia risk evaluation score: a clinically useful predictor of mortality and morbidity after cardiac surgery. *Anesthesiology* 2001; 94: 194-204.
103. Shroyer AL, Coombs LP, Peterson ED, Eiken MC, DeLong ER, Chen A, Ferguson TB, Jr., Grover FL, Edwards FH. The Society of Thoracic Surgeons: 30-day operative mortality and morbidity risk models. *Ann.Thorac.Surg.* 2003; 75: 1856-64.
104. Ahmed I, House CM, Nelson WB. Predictors of inotrope use in patients undergoing concomitant coronary artery bypass graft (CABG) and aortic valve replacement (AVR) surgeries at separation from cardiopulmonary bypass (CPB). *J Cardiothorac.Surg.* 2009; 4: 24.
105. Denault AY, Belisle S, Babin D, Hardy JF. Difficult separation from cardiopulmonary bypass and deltaPCO₂. *Can.J.Anaesth.* 2001; 48: 196-9.
106. Weis F, Kilger E, Beiras-Fernandez A, Nassau K, Reuter D, Goetz A, Lamm P, Reindl L, Briegel J. Association between vasopressor dependence and early outcome in patients after cardiac surgery. *Anaesthesia* 2006; 61: 938-42.
107. Ascione R, Rees K, Santo K, Chamberlain MH, Marchetto G, Taylor F, Angelini GD. Coronary artery bypass grafting in patients over 70 years old: the influence of age and surgical technique on early and mid-term clinical outcomes. *Eur.J Cardiothorac Surg.* 2002; 22: 124-8.
108. Johnson BA, Weil MH. Redefining ischemia due to circulatory failure as dual defects of oxygen deficits and of carbon dioxide excesses. *Crit Care Med.* 1991; 19: 1432-8.
109. Kumbhani DJ, Healey NA, Birjiniuk V, Crittenden MD, Treanor PR, Al-Tabbaa AK, Khuri SF. Intraoperative regional myocardial acidosis predicts the need for inotropic support in cardiac surgery. *Am.J Surg.* 2004; 188: 474-80.
110. Heringlake M, Bahlmann L, Misfeld M, Poeling J, Leptien A, Kraatz E, Klaus S. High myocardial lactate concentration is associated with poor myocardial function prior to cardiopulmonary bypass. *Minerva Anesthesiol.* 2005; 71: 775-83.
111. Turer AT, Stevens RD, Bain JR, Muehlbauer MJ, van der WJ, Mathew JP, Schwinn DA, Glower DD, Newgard CB, Podgoreanu MV. Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. *Circulation* 2009; 119: 1736-46.

112. Maslow AD, Regan MM, Panzica P, Heindel S, Mashikian J, Comunale ME. Precardiopulmonary bypass right ventricular function is associated with poor outcome after coronary artery bypass grafting in patients with severe left ventricular systolic dysfunction. *Anesth Analg.* 2002; 95: 1507-18.
113. Appleton CP, Hatle LK, Popp RL. Superior vena cava and hepatic vein Doppler echocardiography in healthy adults. *J Am Coll. Cardiol.* 1987; 10: 1032-9.
114. Pinto FJ, Wranne B, St Goar FG, Schnittger I, Popp RL. Hepatic venous flow assessed by transesophageal echocardiography. *J. Am. Coll. Cardiol.* 1991; 17: 1493-8.
115. Tuman KJ, McCarthy RJ, March RJ, Najafi H, Ivankovich AD. Morbidity and duration of ICU stay after cardiac surgery. A model for preoperative risk assessment. *Chest* 1992; 102: 36-44.
116. Reich DL, Bodian CA, Krol M, Kuroda M, Osinski T, Thys DM. Intraoperative hemodynamic predictors of mortality, stroke, and myocardial infarction after coronary artery bypass surgery. *Anesth. Analg.* 1999; 89: 814-22.
117. Malouf JF, Enriquez-Sarano M, Pellikka PA, Oh JK, Bailey KR, Chandrasekaran K, Mullany CJ, Tajik AJ. Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. *J. Am. Coll. Cardiol.* 2002; 40: 789-95.
118. Milano AD, Blanzola C, Mecozzi G, D'Alfonso A, De Carlo M, Nardi C, Bortolotti U. Hemodynamic performance of stented and stentless aortic bioprostheses. *Ann. Thorac. Surg.* 2001; 72: 33-8.
119. Rao V, Jamieson WR, Ivanov J, Armstrong S, David TE. Prosthesis-patient mismatch affects survival after aortic valve replacement. *Circulation* 2000; 102: III5-III9.
120. Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prosthesis-patient mismatch in the aortic valve position and its prevention. *J Am. Coll. Cardiol* 2000; 36: 1131-41.
121. Blais C, Dumesnil JG, Baillet R, Simard S, Doyle D, Pibarot P. Impact of valve prosthesis-patient mismatch on short-term mortality after aortic valve replacement. *Circulation* 2003; 108: 983-8.
122. Ruel M, Rubens FD, Masters RG, Pipe AL, Bedard P, Hendry PJ, Lam BK, Burwash IG, Goldstein WG, Brais MP, Keon WJ, Mesana TG. Late incidence and predictors of persistent or recurrent heart failure in patients with aortic prosthetic valves. *J Thorac. Cardiovasc. Surg.* 2004; 127: 149-59.

123. Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical impact, and prevention. *Heart* 2006; 92: 1022-9.
124. Tasca G, Mhagna Z, Perotti S, Centurini PB, Sabatini T, Amaducci A, Brunelli F, Cirillo M, DallaTomba M, Quaini E, Troise G, Pibarot P. Impact of prosthesis-patient mismatch on cardiac events and midterm mortality after aortic valve replacement in patients with pure aortic stenosis. *Circulation* 2006; 113: 570-6.
125. Kulik A, Burwash IG, Kapila V, Mesana TG, Ruel M. Long-term outcomes after valve replacement for low-gradient aortic stenosis: impact of prosthesis-patient mismatch. *Circulation* 2006; 114: I553-I558.
126. Bakhtiary F, Schiemann M, Dzemali O, Dogan S, Schachinger V, Ackermann H, Moritz A, Kleine P. Impact of patient-prosthesis mismatch and aortic valve design on coronary flow reserve after aortic valve replacement. *J.Am.Coll.Cardiol.* 2007; 49: 790-6.
127. Brown J, Shah P, Stanton T, Marwick TH. Interaction and prognostic effects of left ventricular diastolic dysfunction and patient-prosthesis mismatch as determinants of outcome after isolated aortic valve replacement. *Am.J Cardiol.* 2009; 104: 707-12.
128. Magne J, Mathieu P, Dumesnil JG, Tanne D, Dagenais F, Doyle D, Pibarot P. Impact of Prosthesis-Patient Mismatch on Survival After Mitral Valve Replacement. *Circulation* 2007; 115: 1417-25.
129. Leone M, Blidi S, Antonini F, Meyssignac B, Bordon S, Garcin F, Charvet A, Blasco V, Albanese J, Martin C. Oxygen tissue saturation is lower in nonsurvivors than in survivors after early resuscitation of septic shock. *Anesthesiology* 2009; 111: 366-71.
130. Denault AY, Deschamps A, Murkin JM. A proposed algorithm for the intraoperative use of cerebral near-infrared spectroscopy. *Semin Cardiothorac Vasc Anesth* 2007; 11: 274-81.
131. Taylor JH, Mulier KE, Myers DE, Beilman GJ. Use of near-infrared spectroscopy in early determination of irreversible hemorrhagic shock. *J Trauma* 2005; 58: 1119-25.
132. Skhirtladze K, Birkenberg B, Mora B, Moritz A, Ince I, Ankersmit HJ, Steinlechner B, Dworschak M. Cerebral desaturation during cardiac arrest: its relation to arrest duration and left ventricular pump function. *Crit Care Med.* 2009; 37: 471-5.

133. Casati A, Fanelli G, Pietropaoli P, Proietti R, Tufano R, Danelli G, Fierro G, De CG, Servillo G. Continuous monitoring of cerebral oxygen saturation in elderly patients undergoing major abdominal surgery minimizes brain exposure to potential hypoxia. *Anesth.Analg.* 2005; 101: 740-7, table.
134. Murkin JM, Adams SJ, Novick RJ, Quantz M, Bainbridge D, Iglesias I, Cleland A, Schaefer B, Irwin B, Fox S. Monitoring brain oxygen saturation during coronary bypass surgery: a randomized, prospective study. *Anesth.Analg.* 2007; 104: 51-8.
135. Taillefer MC, Denault AY. Cerebral near-infrared spectroscopy in adult heart surgery: systematic review of its clinical efficacy. *Can.J.Anaesth.* 2005; 52: 79-87.
136. Gomes WJ, Erlichman MR, Batista-Filho ML, Knobel M, Almeida DR, Carvalho AC, Catani R, Buffolo E. Vasoplegic syndrome after off-pump coronary artery bypass surgery. *Eur.J Cardiothorac.Surg.* 2003; 23: 165-9.
137. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. *N.Engl.J Med.* 2001; 345: 588-95.
138. Berman M, Stamler A, Sahar G, Georghiou GP, Sharoni E, Brauner R, Medalion B, Vidne BA, Kogan A. Validation of the 2000 Bernstein-Parsonnet score versus the EuroSCORE as a prognostic tool in cardiac surgery. *Ann.Thorac.Surg.* 2006; 81: 537-40.
139. Rady MY, Ryan T, Starr NJ. Perioperative determinants of morbidity and mortality in elderly patients undergoing cardiac surgery. *Crit Care Med.* 1998; 26: 225-35.
140. Gunay R, Sensoz Y, Kayacioglu I, Tuygun AK, Balci AY, Kisa U, Demirtas MM, Yekeler I. Is the aortic valve pathology type different for early and late mortality in concomitant aortic valve replacement and coronary artery bypass surgery? *Interact.Cardiovasc.Thorac.Surg.* 2009; [Epub ahead of print].
141. Nilsson J, Algotsson L, Hognlund P, Luhrs C, Brandt J. Comparison of 19 pre-operative risk stratification models in open-heart surgery. *Eur.Heart J.* 2006; 27: 867-74.
142. Sellke FW, Boyle EM, Jr., Verrier ED. Endothelial cell injury in cardiovascular surgery: the pathophysiology of vasomotor dysfunction. *Ann.Thorac.Surg.* 1996; 62: 1222-8.
143. Blumberg N. Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt. *Transfusion* 2005; 45: 33S-9S.

144. Fransen E, Maessen J, Dentener M, Senden N, Buurman W. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. *Chest* 1999; 116: 1233-9.
145. Redfield MM, Jacobsen SJ, Burnett JC, Jr., Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. *JAMA* 2003; 289: 194-202.
146. Shafique T, Johnson RG, Dai HB, Weintraub RM, Sellke FW. Altered pulmonary microvascular reactivity after total cardiopulmonary bypass. *J Thorac.Cardiovasc.Surg.* 1993; 106: 479-86.
147. Cooper WA, O'Brien SM, Thourani VH, Guyton RA, Bridges CR, Szczech LA, Petersen R, Peterson ED. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. *Circulation* 2006; 113: 1063-70.
148. Cheatham ML, Malbrain ML, Kirkpatrick A, Sugrue M, Parr M, De WJ, Balogh Z, Leppaniemi A, Olvera C, Ivatury R, D'Amours S, Wendon J, Hillman K, Wilmer A. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. II. Recommendations. *Intensive Care Med.* 2007; 33: 951-62.
149. Jacobsohn E, Avidan MS, Hantler CB, Rosemeier F, De Wet CJ. Case report: inferior vena-cava right atrial anastomotic stenosis after bicaval orthotopic heart transplantation. *Can.J Anaesth.* 2006; 53: 1039-43.
150. Bryan AJ, Barzilai B, Kouchoukos NT. Transesophageal echocardiography and adult cardiac operations. *Ann.Thorac.Surg.* 1995; 59: 773-9.
151. Bergquist BD, Bellows WH, Leung JM. Transesophageal echocardiography in myocardial revascularization: II. Influence on intraoperative decision making. *Anesth Analg.* 1996; 82: 1139-45.
152. Mishra M, Chauhan R, Sharma KK, Dhar A, Bhise M, Dhole S, Omar A, Kasliwal RR, Trehan N. Real-time intraoperative transesophageal echocardiography--how useful? Experience of 5,016 cases. *J.Cardiothorac Vasc Anesth* 1998; 12: 625-32.
153. Click RL, Abel MD, Schaff HV. Intraoperative transesophageal echocardiography: 5-year prospective review of impact on surgical management. *Mayo Clin.Proc.* 2000; 75: 241-7.
154. Practice guidelines for perioperative transesophageal echocardiography. A report by the American Society of Anesthesiologists and the Society of Cardiovascular

Anesthesiologists Task Force on Transesophageal Echocardiography.
Anesthesiology 1996; 84: 986-1006.

155. Merello L, Riesle E, Albuquerque J, Torres H, ranguiz-Santander E, Pedemonte O, Westerberg B. Risk scores do not predict high mortality after coronary artery bypass surgery in the presence of diastolic dysfunction. *Ann.Thorac.Surg.* 2008; 85: 1247-55.
156. Jacobsohn E, Chorn R, O'Connor M. The role of the vasculature in regulating venous return and cardiac output: historical and graphical approach. *Can.J Anaesth.* 1997; 44: 849-67.
157. Dell'Italia LJ, Walsh RA. Application of a time varying elastance model to right ventricular performance in man. *Cardiovasc.Res.* 1988; 22: 864-74.
158. Deslauriers N, Dery R, Denault A. Acute abdominal compartment syndrome. *Can.J Anaesth.* 2009; 56: 678-82.
159. Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD, Smith CR, Jr., Rose EA, Landry DW, Oz MC. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. *J Thorac.Cardiovasc.Surg.* 1998; 116: 973-80.
160. Morales DL, Gregg D, Helman DN, Williams MR, Naka Y, Landry DW, Oz MC. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. *Ann.Thorac.Surg.* 2000; 69: 102-6.
161. Morales DL, Garrido MJ, Madigan JD, Helman DN, Faber J, Williams MR, Landry DW, Oz MC. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. *Ann.Thorac.Surg.* 2003; 75: 926-30.
162. Talbot MP, Tremblay I, Denault AY, Belisle S. Vasopressin for refractory hypotension during cardiopulmonary bypass. *J.Thorac.Cardiovasc.Surg.* 2000; 120: 401-2.
163. Viaro F, Dalio MB, Evora PR. Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated: should methylene blue be the treatment of choice? *Chest* 2002; 122: 1061-6.
164. Ocal A, Kiris I, Erdinc M, Peker O, Yavuz T, Ibrisim E. Efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertension. *Tohoku J Exp.Med.* 2005; 207: 51-8.

165. Serrano N, Jimenez JJ, Brouard MT, Malaga J, Mora ML. Acute adrenal insufficiency after cardiac surgery. *Crit Care Med.* 2000; 28: 569-70.
166. Gomes WJ, Carvalho AC, Palma JH, Goncalves I, Jr., Buffolo E. Vasoplegic syndrome: a new dilemma. *J Thorac.Cardiovasc.Surg.* 1994; 107: 942-3.
167. Leyh RG, Kofidis T, Struber M, Fischer S, Knobloch K, Wachsmann B, Hagl C, Simon AR, Haverich A. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? *J Thorac.Cardiovasc.Surg.* 2003; 125: 1426-31.
168. Edmunds LH, Jr. Why cardiopulmonary bypass makes patients sick: strategies to control the blood-synthetic surface interface. *Adv.Card Surg.* 1995; 6: 131-67.
169. Kim PK, Deutschman CS. Inflammatory responses and mediators. *Surg.Clin.North Am.* 2000; 80: 885-94.
170. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. *Crit Care Med.* 2002; 30: S294-S301.
171. Gersh BJ, Kronmal RA, Frye RL, Schaff HV, Ryan TJ, Gosselin AJ, Kaiser GC, Killip T, III. Coronary arteriography and coronary artery bypass surgery: morbidity and mortality in patients ages 65 years or older. A report from the Coronary Artery Surgery Study. *Circulation* 1983; 67: 483-91.
172. Leung JM, O'Kelly B, Browner WS, Tubau J, Hollenberg M, Mangano DT. Prognostic importance of postbypass regional wall-motion abnormalities in patients undergoing coronary artery bypass graft surgery. SPI Research Group. *Anesthesiology* 1989; 71: 16-25.
173. Khouri SJ, Maly GT, Suh DD, Walsh TE. A practical approach to the echocardiographic evaluation of diastolic function. *J.Am.Soc.Echocardiogr.* 2004; 17: 290-7.
174. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. *J Am.Soc.Echocardiogr.* 2009; 22: 107-33.
175. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. *J Am.Coll.Cardiol.* 1997; 30: 8-18.

176. Vanoverschelde JL, Raphael DA, Robert AR, Cosyns JR. Left ventricular filling in dilated cardiomyopathy: relation to functional class and hemodynamics. *J.Am.Coll.Cardiol.* 1990; 15: 1288-95.
177. Pinamonti B, Di Lenarda A, Sinagra G, Camerini F. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. Heart Muscle Disease Study Group. *J.Am.Coll.Cardiol.* 1993; 22: 808-15.
178. Rihal CS, Nishimura RA, Hatle LK, Bailey KR, Tajik AJ. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. *Circulation* 1994; 90: 2772-9.
179. Giannuzzi P, Temporelli PL, Bosimini E, Silva P, Imparato A, Corra U, Galli M, Giordano A. Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. *J.Am.Coll.Cardiol.* 1996; 28: 383-90.
180. Munt B, Jue J, Gin K, Fenwick J, Tweeddale M. Diastolic filling in human severe sepsis: an echocardiographic study. *Crit Care Med.* 1998; 26: 1829-33.
181. Poulsen SH, Moller JE, Norager B, Egstrup K. Prognostic implications of left ventricular diastolic dysfunction with preserved systolic function following acute myocardial infarction. *Cardiology* 2001; 95: 190-7.
182. Moller JE, Poulsen SH, Sondergaard E, Seward JB, Appleton CP, Egstrup K. Impact of early changes in left ventricular filling pattern on long-term outcome after acute myocardial infarction. *Int.J Cardiol.* 2003; 89: 207-15.
183. O'Connor GT, Plume SK, Olmstead EM, Coffin LH, Morton JR, Maloney CT, Nowicki ER, Levy DG, Tryzelaar JF, Hernandez F. Multivariate prediction of in-hospital mortality associated with coronary artery bypass graft surgery. Northern New England Cardiovascular Disease Study Group. *Circulation* 1992; 85: 2110-8.
184. Vaskelyte J, Stoskute N, Kinduris S, Ereminiene E. Coronary artery bypass grafting in patients with severe left ventricular dysfunction: predictive significance of left ventricular diastolic filling pattern. *Eur.J.Echocardiogr.* 2001; 2: 62-7.
185. Liu J, Tanaka N, Murata K, Ueda K, Wada Y, Oyama R, Matsuzaki M. Prognostic value of pseudonormal and restrictive filling patterns on left ventricular remodeling and cardiac events after coronary artery bypass grafting. *Am.J.Cardiol.* 2003; 91: 550-4.

186. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *J Am.Soc.Echocardiogr.* 2005; 18: 1440-63.
187. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. *Circulation* 2008; 117: 1436-48.
188. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: Pathophysiology, clinical importance, and management of right ventricular failure. *Circulation* 2008; 117: 1717-31.
189. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. *Ann.Intern.Med.* 1991; 115: 343-9.
190. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. *Am.J Cardiol.* 1998; 81: 1157-61.
191. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. *Circulation* 2006; 114: 1883-91.
192. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. *Coron.Artery Dis.* 2005; 16: 13-8.
193. Pinzani A, de GG, Pinzani V, Ninet J, Milon H, Delahaye JP. [Pre- and postoperative right cardiac insufficiency in patients with mitral or mitral-aortic valve diseases]. *Arch.Mal Coeur Vaiss.* 1993; 86: 27-34.
194. Cullen S, Shore D, Redington A. Characterization of right ventricular diastolic performance after complete repair of tetralogy of Fallot. Restrictive physiology predicts slow postoperative recovery. *Circulation* 1995; 91: 1782-9.
195. Gatzoulis MA, Clark AL, Cullen S, Newman CG, Redington AN. Right ventricular diastolic function 15 to 35 years after repair of tetralogy of Fallot.

- Restrictive physiology predicts superior exercise performance. *Circulation* 1995; 91: 1775-81.
196. Kormos RL, Gasior TA, Kawai A, Pham SM, Murali S, Hattler BG, Griffith BP. Transplant candidate's clinical status rather than right ventricular function defines need for univentricular versus biventricular support. *J Thorac.Cardiovasc.Surg.* 1996; 111: 773-82.
 197. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000. *J Heart Lung Transplant.* 2000; 19: 909-31.
 198. Therrien J, Provost Y, Merchant N, Williams W, Colman J, Webb G. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. *Am J Cardiol.* 2005; 95: 779-82.
 199. Davlouros PA, Niwa K, Webb G, Gatzoulis MA. The right ventricle in congenital heart disease. *Heart* 2006; 92 Suppl 1: i27-i38.
 200. Nashef SA, Roques F, Hammill BG, Peterson ED, Michel P, Grover FL, Wyse RK, Ferguson TB. Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery. *Eur.J.Cardiothorac.Surg.* 2002; 22: 101-5.
 201. Ambler G, Omar RZ, Royston P, Kinsman R, Keogh BE, Taylor KM. Generic, simple risk stratification model for heart valve surgery. *Circulation* 2005; 112: 224-31.
 202. Boldt J, Zickmann B, Ballesteros M, Dapper F, Hempelmann G. Right ventricular function in patients with aortic stenosis undergoing aortic valve replacement. *J.Cardiothorac.Vasc.Anesth.* 1992; 6: 287-91.
 203. Wencker D, Borer JS, Hochreiter C, Devereux RB, Roman MJ, Kligfield P, Supino P, Krieger K, Isom OW. Preoperative predictors of late postoperative outcome among patients with nonischemic mitral regurgitation with 'high risk' descriptors and comparison with unoperated patients. *Cardiology* 2000; 93: 37-42.
 204. Klein AL, Hatle LK, Burstow DJ, Taliercio CP, Seward JB, Kyle RA, Bailey KR, Gertz MA, Tajik AJ. Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. *J.Am.Coll.Cardiol.* 1990; 15: 99-108.
 205. Pye MP, Pringle SD, Cobbe SM. Reference values and reproducibility of Doppler echocardiography in the assessment of the tricuspid valve and right ventricular diastolic function in normal subjects. *Am.J Cardiol.* 1991; 67: 269-73.

206. Nomura T, Lebowitz L, Koide Y, Keehn L, Oka Y. Evaluation of hepatic venous flow using transesophageal echocardiography in coronary artery bypass surgery: an index of right ventricular function. *J. Cardiothorac Vasc Anesth* 1995; 9: 9-17.
207. Caso P, Galderisi M, Cicala S, Cioppa C, D'Andrea A, Lagioia G, Liccardo B, Martiniello AR, Mininni N. Association between myocardial right ventricular relaxation time and pulmonary arterial pressure in chronic obstructive lung disease: analysis by pulsed Doppler tissue imaging. *J Am.Soc.Echocardiogr.* 2001; 14: 970-7.
208. Ozer N, Tokgozoglu L, Coplu L, Kes S. Echocardiographic evaluation of left and right ventricular diastolic function in patients with chronic obstructive pulmonary disease. *J Am.Soc.Echocardiogr.* 2001; 14: 557-61.
209. Mixon TA, Giebel DW. Abnormal diastolic flow demonstrated by color M mode echocardiography in hypertrophic cardiomyopathy with mid-ventricular cavity obliteration. *Echocardiography.* 2004; 21: 49-53.
210. Martinez MW, Sorajja P, Ommen SR. Mid-cavitary obstruction in hypertrophic cardiomyopathy. *Heart* 2008; 94: 1287.
211. Rochon AG, L'allier PL, Denault AY. Always consider left ventricular outflow tract obstruction in hemodynamically unstable patients. *Can.J Anaesth.* 2009.
212. Maslow AD, Regan MM, Haering JM, Johnson RG, Levine RA. Echocardiographic predictors of left ventricular outflow tract obstruction and systolic anterior motion of the mitral valve after mitral valve reconstruction for myxomatous valve disease. *J Am Coll.Cardiol.* 1999; 34: 2096-104.
213. Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. *J Am.Coll.Cardiol.* 2000; 36: 1344-54.
214. Bartunek J, Sys SU, Rodrigues AC, van Schuerbeeck E, Mortier L, de Bruyne B. Abnormal systolic intraventricular flow velocities after valve replacement for aortic stenosis. Mechanisms, predictive factors, and prognostic significance. *Circulation* 1996; 93: 712-9.
215. Schwinger ME, O'Brien F, Freedberg RS, Kronzon I. Dynamic left ventricular outflow obstruction after aortic valve replacement: a Doppler echocardiographic study. *J Am.Soc.Echocardiogr.* 1990; 3: 205-8.
216. Lee KS, Stewart WJ, Lever HM, Underwood PL, Cosgrove DM. Mechanism of outflow tract obstruction causing failed mitral valve repair. Anterior displacement of leaflet coaptation. *Circulation* 1993; 88: II24-II29.

217. Jebara VA, Mihaileanu S, Acar C, Brizard C, Grare P, Latremouille C, Chauvaud S, Fabiani JN, Deloche A, Carpentier A. Left ventricular outflow tract obstruction after mitral valve repair. Results of the sliding leaflet technique. *Circulation* 1993; 88: II30-II34.
218. Heidenreich PA, Stainback RF, Redberg RF, Schiller NB, Cohen NH, Foster E. Transesophageal echocardiography predicts mortality in critically ill patients with unexplained hypotension. *J Am Coll. Cardiol.* 1995; 26: 152-8.
219. Doshi SN, Kim MC, Sharma SK, Fuster V. Images in cardiovascular medicine. Right and left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. *Circulation* 2002; 106: e3-e4.
220. Agarwal S, Choudhary S, Saxena A, Ray R, Airan B. Giant pulmonary artery aneurysm with right ventricular outflow tract obstruction. *Indian Heart J.* 2002; 54: 77-9.
221. Tardif JC, Taylor K, Pandian NG, Schwartz S, Rastegar H. Right ventricular outflow tract and pulmonary artery obstruction by postoperative mediastinal hematoma: delineation by multiplane transesophageal echocardiography. *J. Am. Soc. Echocardiogr.* 1994; 7: 400-4.
222. Dall'Agata A, Cromme-Dijkhuis AH, Meijboom FJ, Spitaels SE, McGhie JS, Roelandt JR, Bogers AJ. Use of three-dimensional echocardiography for analysis of outflow obstruction in congenital heart disease. *Am J Cardiol.* 1999; 83: 921-5.
223. Bennink GB, Hitchcock FJ, Molenschot M, Hutter P, Sreeram N. Aneurysmal pericardial patch producing right ventricular inflow obstruction. *Ann. Thorac. Surg.* 2001; 71: 1346-7.
224. Basaria S, Denktas AE, Ghani M, Thandroyen F. Ventricular septal defect patch causing right ventricular inflow tract obstruction. *Circulation* 1999; 100: e12-e13.
225. Therrien J, Dore A, Gersony W, Iserin L, Liberthson R, Meijboom F, Colman JM, Oechslin E, Taylor D, Perloff J, Somerville J, Webb GD. CCS Consensus Conference 2001 update: recommendations for the management of adults with congenital heart disease. Part I. *Can. J. Cardiol.* 2001; 17: 940-59.
226. Therrien J, Gatzoulis M, Graham T, Bink-Boelkens M, Connelly M, Niwa K, Mulder B, Pyeritz R, Perloff J, Somerville J, Webb GD. Canadian Cardiovascular Society Consensus Conference 2001 update: Recommendations for the Management of Adults with Congenital Heart Disease--Part II. *Can. J. Cardiol.* 2001; 17: 1029-50.

227. Therrien J, Warnes C, Daliento L, Hess J, Hoffmann A, Marelli A, Thilen U, Presbitero P, Perloff J, Somerville J, Webb GD. Canadian Cardiovascular Society Consensus Conference 2001 update: recommendations for the management of adults with congenital heart disease part III. *Can.J Cardiol.* 2001; 17: 1135-58.
228. Stierle U, Sheikhzadeh A, Shakibi JG, Langbehn AF, Diederich KW. Right ventricular obstruction in various types of hypertrophic cardiomyopathy. *Jpn.Heart J.* 1987; 28: 115-25.
229. Kirshbom PM, Tapson VF, Harrison JK, Davis RD, Gaynor JW. Delayed right heart failure following lung transplantation. *Chest* 1996; 109: 575-7.
230. Gorcsan J, III, Reddy SC, Armitage JM, Griffith BP. Acquired right ventricular outflow tract obstruction after lung transplantation: diagnosis by transesophageal echocardiography. *J.Am.Soc.Echocardiogr.* 1993; 6: 324-6.
231. Werner AM, Darrell JC, Pallegri RV, Woelfel GF, Grant K, Marrangoni AG. Right ventricular outflow obstruction with intact ventricular septum in adults. *Tex.Heart Inst.J.* 1997; 24: 105-8.
232. Pibarot P, Dumesnil JG, Cartier PC, Metras J, Lemieux MD. Patient-prosthesis mismatch can be predicted at the time of operation. *Ann.Thorac.Surg.* 2001; 71: S265-S268.
233. Derouin M, Couture P, Boudreault D, Girard D, Gravel D. Detection of gas embolism by transesophageal echocardiography during laparoscopic cholecystectomy. *Anesth Analg.* 1996; 82: 119-24.
234. Chavanon O, Tremblay I, Delay D, Bouveret A, Blain R, Perrault LP. Carbon dioxide embolism during endoscopic saphenectomy for coronary artery bypass surgery. *J Thorac.Cardiovasc.Surg.* 1999; 118: 557-8.
235. Sukernik MR, Bennett-Guerrero E. The incidental finding of a patent foramen ovale during cardiac surgery: should it always be repaired? A core review. *Anesth Analg.* 2007; 105: 602-10.
236. Krasuski RA, Hart SA, Allen D, Qureshi A, Pettersson G, Houghtaling PL, Batizy LH, Blackstone E. Prevalence and repair of intraoperatively diagnosed patent foramen ovale and association with perioperative outcomes and long-term survival. *JAMA* 2009; 302: 290-7.
237. Ebata T, Watanabe Y, Amaha K, Hosaka Y, Takagi S. Haemodynamic changes during the apnoea test for diagnosis of brain death. *Can.J.Anaesth.* 1991; 38: 436-40.

238. Kiely DG, Cargill RI, Lipworth BJ. Effects of hypercapnia on hemodynamic, inotropic, lusitropic, and electrophysiologic indices in humans. *Chest* 1996; 109: 1215-21.
239. Malbrain ML, Cheatham ML, Kirkpatrick A, Sugrue M, Parr M, De WJ, Balogh Z, Leppaniemi A, Olvera C, Ivatury R, D'Amours S, Wendon J, Hillman K, Johansson K, Kolkman K, Wilmer A. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. I. Definitions. *Intensive Care Med.* 2006; 32: 1722-32.
240. Durand M, Lamarche Y, Denault A. Pericardial tamponade. *Can.J Anaesth.* 2009; 56: 443-8.
241. Wechsler AS, Auerbach BJ, Graham TC, Sabiston DC, Jr. Distribution of intramyocardial blood flow during pericardial tamponade. Correlation with microscopic anatomy and intrinsic myocardial contractility. *J.Thorac.Cardiovasc.Surg.* 1974; 68: 847-56.
242. Lichtenstein DA, Meziere GA. Relevance of lung ultrasound in the diagnosis of acute respiratory failure: the BLUE protocol. *Chest* 2008; 134: 117-25.
243. Sugrue M. Abdominal compartment syndrome. *Curr.Opin.Crit Care* 2005; 11: 333-8.
244. Malbrain ML, Chiumello D, Pelosi P, Bihari D, Innes R, Ranieri VM, Del TM, Wilmer A, Brienza N, Malcangi V, Cohen J, Japiassu A, De Keulenaer BL, Daelemans R, Jacquet L, Laterre PF, Frank G, de SP, Cesana B, Gattinoni L. Incidence and prognosis of intraabdominal hypertension in a mixed population of critically ill patients: a multiple-center epidemiological study. *Crit Care Med.* 2005; 33: 315-22.
245. Kron IL, Harman PK, Nolan SP. The measurement of intra-abdominal pressure as a criterion for abdominal re-exploration. *Ann.Surg.* 1984; 199: 28-30.
246. An G, West MA. Abdominal compartment syndrome: a concise clinical review. *Crit Care Med.* 2008; 36: 1304-10.
247. De Waele JJ, Hoste EA, Malbrain ML. Decompressive laparotomy for abdominal compartment syndrome--a critical analysis. *Crit Care* 2006; 10: R51.
248. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM, Antman EM, Smith SC, Jr., Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO. ACC/AHA/ASE 2003 guideline update for the clinical

- application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). *Circulation* 2003; 108: 1146-62.
249. Madsen PL, Nielsen HB, Christiansen P. Well-being and cerebral oxygen saturation during acute heart failure in humans. *Clin.Physiol* 2000; 20: 158-64.
 250. Koike A, Itoh H, Oohara R, Hoshimoto M, Tajima A, Aizawa T, Fu LT. Cerebral oxygenation during exercise in cardiac patients. *Chest* 2004; 125: 182-90.
 251. Sokol DK, Markand ON, Daly EC, Luerssen TG, Malkoff MD. Near infrared spectroscopy (NIRS) distinguishes seizure types. *Seizure*. 2000; 9: 323-7.
 252. Shojima M, Watanabe E, Mayanagi Y. Cerebral blood oxygenation after cerebrospinal fluid removal in hydrocephalus measured by near infrared spectroscopy. *Surg.Neurol.* 2004; 62: 312-8.
 253. Gracias VH, Guillamondegui OD, Stiefel MF, Wilensky EM, Bloom S, Gupta R, Pryor JP, Reilly PM, Leroux PD, Schwab CW. Cerebral cortical oxygenation: a pilot study. *J Trauma* 2004; 56: 469-72.
 254. Vernieri F, Tibuzzi F, Pasqualetti P, Rosato N, Passarelli F, Rossini PM, Silvestrini M. Transcranial Doppler and near-infrared spectroscopy can evaluate the hemodynamic effect of carotid artery occlusion. *Stroke* 2004; 35: 64-70.
 255. Kurth CD, Steven JL, Montenegro LM, Watzman HM, Gaynor JW, Spray TL, Nicolson SC. Cerebral oxygen saturation before congenital heart surgery. *Ann.Thorac.Surg.* 2001; 72: 187-92.
 256. Staal EM, de Heer M, Jukema JW, Koning G, van der Wall EE, Reiber JH, Baan J, Steendijk P. End-diastolic and end-systolic volume from the left ventricular angiogram: how accurate is visual frame selection? Comparison between visual and semi-automated computer-assisted analysis. *Int.J.Cardiovasc.Imaging* 2003; 19: 259-66.
 257. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. *J.Am.Soc.Echocardiogr.* 1989; 2: 358-67.
 258. Paul AK, Nabi HA. Gated myocardial perfusion SPECT: basic principles, technical aspects, and clinical applications. *J.Nucl.Med.Technol.* 2004; 32: 179-87.

259. Hammermeister KE, Kennedy JW. Predictors of surgical mortality in patients undergoing direct myocardial revascularization. *Circulation* 1974; 50: III12-III15.
260. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH, Mangano DT. A multicenter risk index for atrial fibrillation after cardiac surgery. *JAMA* 2004; 291: 1720-9.
261. Mitchell LB, Exner DV, Wyse DG, Connolly CJ, Prystai GD, Bayes AJ, Kidd WT, Kieser T, Burgess JJ, Ferland A, MacAdams CL, Maitland A. Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial. *JAMA* 2005; 294: 3093-100.
262. Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVliet M, Collins JJ, Jr., Cohn LH, Burstin HR. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. *Circulation* 1996; 94: 390-7.
263. Mathew JP, Parks R, Savino JS, Friedman AS, Koch C, Mangano DT, Browner WS. Atrial fibrillation following coronary artery bypass graft surgery: predictors, outcomes, and resource utilization. MultiCenter Study of Perioperative Ischemia Research Group. *JAMA* 1996; 276: 300-6.
264. Villareal RP, Hariharan R, Liu BC, Kar B, Lee VV, Elayda M, Lopez JA, Rasekh A, Wilson JM, Massumi A. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. *J Am.Coll.Cardiol.* 2004; 43: 742-8.
265. Daoud EG, Strickberger SA, Man KC, Goyal R, Deeb GM, Bolling SF, Pagani FD, Bitar C, Meissner MD, Morady F. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. *N.Engl.J.Med.* 1997; 337: 1785-91.
266. Guarnieri T, Nolan S, Gottlieb SO, Dudek A, Lowry DR. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial. *J.Am.Coll.Cardiol.* 1999; 34: 343-7.
267. Giri S, White CM, Dunn AB, Felton K, Freeman-Bosco L, Reddy P, Tsikouris JP, Wilcox HA, Kluger J. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. *Lancet* 2001; 357: 830-6.
268. White CM, Giri S, Tsikouris JP, Dunn A, Felton K, Reddy P, Kluger J. A comparison of two individual amiodarone regimens to placebo in open heart surgery patients. *Ann.Thorac.Surg.* 2002; 74: 69-74.

269. White CM, Caron MF, Kalus JS, Rose H, Song J, Reddy P, Gallagher R, Kluger J. Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation: the Atrial Fibrillation Suppression Trial II (AFIST II). *Circulation* 2003; 108 Suppl 1: II200-II206.
270. Bonow RO, Carabello BA, Kanu C, de LA, Jr., Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'gara PT, O'rourke RA, Otto CM, Shah PM, Shanewise JS, Smith SC, Jr., Jacobs AK, Adams CD, Anderson JL, Antman EM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. *Circulation* 2006; 114: e84-231.
271. Schnittger I, Fitzgerald PJ, Daughters GT, Ingels NB, Kantrowitz NE, Schwarzkopf A, Mead CW, Popp RL. Limitations of comparing left ventricular volumes by two dimensional echocardiography, myocardial markers and cineangiography. *Am.J Cardiol.* 1982; 50: 512-9.
272. Fleiss JL. *Statistical methods for rates and proportions.* 2nd edn. New York: Wiley, 1981.
273. Winer BJ. *Statistical principles in experimental design.* 2nd ed edn. New York: McGraw-Hill, 1971.
274. Dini FL, Dell'Anna R, Micheli A, Michelassi C, Rovai D. Impact of blunted pulmonary venous flow on the outcome of patients with left ventricular systolic dysfunction secondary to either ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol.* 2000; 85: 1455-60.
275. Sheldon RS, Mitchell LB, Duff HJ, Wyse DG, Manyari DE. Right and left ventricular function during chronic amiodarone therapy. *Am.J Cardiol.* 1988; 62: 736-40.
276. Pfisterer M, Burkart F, Muller-Brand J, Kiowski W. Important differences between short- and long-term hemodynamic effects of amiodarone in patients with chronic ischemic heart disease at rest and during ischemia-induced left ventricular dysfunction. *J Am.Coll.Cardiol.* 1985; 5: 1205-11.
277. Hohnloser SH, Meinertz T, Dammbacher T, Steiert K, Jahnchen E, Zehender M, Fraedrich G, Just H. Electrocardiographic and antiarrhythmic effects of

- intravenous amiodarone: results of a prospective, placebo-controlled study. *Am.Heart J* 1991; 121: 89-95.
278. Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. *Ann.Intern.Med.* 1997; 127: 294-303.
 279. Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. *Chest* 1997; 112: 676-92.
 280. Modry DL, Chiu RC. Pulmonary reperfusion syndrome. *Ann.Thorac.Surg.* 1979; 27: 206-15.
 281. Assanelli D, Lew WY, Shabetai R, LeWinter MM. Influence of the pericardium on right and left ventricular filling in the dog. *J Appl.Physiol* 1987; 63: 1025-32.
 282. Nishimura RA, Abel MD, Hatle LK, Tajik AJ. Relation of pulmonary vein to mitral flow velocities by transesophageal Doppler echocardiography. Effect of different loading conditions. *Circulation* 1990; 81: 1488-97.
 283. Breisblatt WM, Stein KL, Wolfe CJ, Follansbee WP, Capozzi J, Armitage JM, Hardesty RL. Acute myocardial dysfunction and recovery: a common occurrence after coronary bypass surgery. *J Am.Coll.Cardiol.* 1990; 15: 1261-9.
 284. Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". *J Am.Coll.Cardiol.* 1986; 8: 1467-70.
 285. Lappas DG, Skubas NJ, Lappas GD, Ruocco E, Tambassis E, Pasque M. Prevalence of left ventricular diastolic filling abnormalities in adult cardiac surgical patients: an intraoperative echocardiographic study. *Semin Thorac.Cardiovasc.Surg.* 1999; 11: 125-33.
 286. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC, Jr., Klein WW, onso-Garcia A, Blomstrom-Lundqvist C, de BG, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. *Circulation* 2001; 104: 2118-50.

287. Gelissen HP, Epema AH, Henning RH, Krijnen HJ, Hennis PJ, den HA. Inotropic effects of propofol, thiopental, midazolam, etomidate, and ketamine on isolated human atrial muscle. *Anesthesiology* 1996; 84: 397-403.
288. Hanton G, Gautier M, Bonnet P, Herbet A. Effect of milrinone on echocardiographic parameters after single dose in Beagle dogs and relationship with drug-induced cardiotoxicity. *Toxicol.Lett.* 2005; 155: 307-17.
289. Cuffe MS, Califf RM, Adams KF, Jr., Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. *JAMA* 2002; 287: 1541-7.
290. Fleming GA, Murray KT, Yu C, Byrne JG, Greelish JP, Petracek MR, Hoff SJ, Ball SK, Brown NJ, Pretorius M. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. *Circulation* 2008; 118: 1619-25.
291. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. *J Am Coll.Cardiol.* 1997; 30: 1527-33.
292. Combes A, Arnoult F, Trouillet JL. Tissue Doppler imaging estimation of pulmonary artery occlusion pressure in ICU patients. *Intensive Care Med.* 2004; 30: 75-81.
293. Royse CF, Barrington MJ, Royse AG. Transesophageal echocardiography values for left ventricular end-diastolic area and pulmonary vein and mitral inflow Doppler velocities in patients undergoing coronary artery bypass graft surgery. *J Cardiothorac.Vasc.Anesth* 2000; 14: 130-2.
294. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. *N.Engl.J Med.* 1991; 325: 1468-75.
295. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghiade M, O'Connor CM. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. *J.Am.Coll.Cardiol.* 2003; 41: 997-1003.
296. Gomez CM, Palazzo MG. Pulmonary artery catheterization in anaesthesia and intensive care. *Br.J.Anaesth.* 1998; 81: 945-56.

297. Lesage AM, Tsuchioka H, Young WG, Jr., Sealy WC. Pathogenesis of pulmonary damage during extracorporeal perfusion. *Arch.Surg.* 1966; 93: 1002-8.
298. Downing SW, Edmunds LH, Jr. Release of vasoactive substances during cardiopulmonary bypass. *Ann.Thorac.Surg.* 1992; 54: 1236-43.
299. Asimakopoulos G, Smith PL, Ratnatunga CP, Taylor KM. Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. *Ann.Thorac.Surg.* 1999; 68: 1107-15.
300. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. *Anesthesiology* 2002; 97: 215-52.
301. Sukernik MR, Mets B, Bennett-Guerrero E. Patent foramen ovale and its significance in the perioperative period. *Anesth Analg.* 2001; 93: 1137-46.
302. Fischer LG, Van AH, Burkle H. Management of pulmonary hypertension: physiological and pharmacological considerations for anesthesiologists. *Anesth.Analg.* 2003; 96: 1603-16.
303. Farber HW, Loscalzo J. Pulmonary arterial hypertension. *N.Engl.J Med.* 2004; 351: 1655-65.
304. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. *Circulation* 2006; 114: 1417-31.
305. Rubin LJ. Primary pulmonary hypertension. *Chest* 1993; 104: 236-50.
306. Ramakrishna G, Sprung J, Ravi BS, Chandrasekaran K, McGoon MD. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. *J Am.Coll.Cardiol.* 2005; 45: 1691-9.
307. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. *Chest* 1989; 95: 2S-4S.
308. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet* 2001; 357: 1191-4.
309. Hachenberg T, Mollhoff T, Holst D, Hammel D, Brussel T. Cardiopulmonary effects of enoximone or dobutamine and nitroglycerin on mitral valve regurgitation and pulmonary venous hypertension. *Journal of cardiothoracic and vascular anesthesia* 1997; 11: 453-7.

310. Schmid ER, Burki C, Engel MH, Schmidlin D, Tornic M, Seifert B. Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgery. *Anesth Analg.* 1999; 89: 1108-15.
311. Solina A, Papp D, Ginsberg S, Krause T, Grubb W, Scholz P, Pena LL, Cody R. A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. *J.Cardiothorac.Vasc.Anesth.* 2000; 14: 12-7.
312. Solina AR, Ginsberg SH, Papp D, Grubb WR, Scholz PM, Pantin EJ, Cody RP, Krause TJ. Dose response to nitric oxide in adult cardiac surgery patients. *J Clin.Anesth* 2001; 13: 281-6.
313. Feneck RO, Sherry KM, Withington PS, Oduro-Dominah A. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. *J.Cardiothorac.Vasc.Anesth.* 2001; 15: 306-15.
314. Fattouch K, Sbraga F, Bianco G, Speziale G, Gucciardo M, Sampognaro R, Ruvolo G. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. *J.Card Surg.* 2005; 20: 171-6.
315. Stafford-Smith M, Lefrak EA, Qazi AG, Welsby IJ, Barber L, Hoefl A, Dorenbaum A, Mathias J, Rochon JJ, Newman MF. Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. *Anesthesiology* 2005; 103: 229-40.
316. Fattouch K, Sbraga F, Sampognaro R, Bianco G, Gucciardo M, Lavallo C, Vizza CD, Fedele F, Ruvolo G. Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study. *J Cardiovasc.Med.(Hagerstown.)* 2006; 7: 119-23.
317. Rex S, Schaelte G, Metzelder S, Flier S, de Waal EE, Autschbach R, Rossaint R, Buhre W. Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. *Acta Anaesthesiol.Scand.* 2008; 52: 65-72.
318. Michel-Cherqui M, Brusset A, Liu N, Raffin L, Schlumberger S, Ceddaha A, Fischler M. Intraoperative transesophageal echocardiographic assessment of vascular anastomoses in lung transplantation. A report on 18 cases. *Chest* 1997; 111: 1229-35.
319. Baim DS, McDowell AV, Cherniles J, Monrad ES, Parker JA, Edelson J, Braunwald E, Grossman W. Evaluation of a new bipyridine inotropic agent--

- milrinone--in patients with severe congestive heart failure. *N.Engl.J Med.* 1983; 309: 748-56.
320. Kikura M, Lee MK, Safon RA, Bailey JM, Levy JH. The effects of milrinone on platelets in patients undergoing cardiac surgery. *Anesth Analg.* 1995; 81: 44-8.
 321. Doolan LA, Jones EF, Kalman J, Buxton BF, Tonkin AM. A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass. *J.Cardiothorac.Vasc.Anesth.* 1997; 11: 37-41.
 322. Kikura M, Levy JH, Michelsen LG, Shanewise JS, Bailey JM, Sadel SM, Szlam F. The effect of milrinone on hemodynamics and left ventricular function after emergence from cardiopulmonary bypass. *Anesth Analg.* 1997; 85: 16-22.
 323. Rathmell JP, Prielipp RC, Butterworth JF, Williams E, Villamaria F, Testa L, Viscomi C, Ittleman FP, Baisden CE, Royster RL. A multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgery. *Anesth.Analg.* 1998; 86: 683-90.
 324. Lobato EB, Florete O, Jr., Bingham HL. A single dose of milrinone facilitates separation from cardiopulmonary bypass in patients with pre-existing left ventricular dysfunction. *Br.J.Anaesth.* 1998; 81: 782-4.
 325. Mollhoff T, Loick HM, Van Aken H, Schmidt C, Rolf N, Tjan TD, Asfour B, Berendes E. Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB). *Anesthesiology* 1999; 90: 72-80.
 326. McNicol L, Andersen LW, Liu G, Doolan L, Baek L. Markers of splanchnic perfusion and intestinal translocation of endotoxins during cardiopulmonary bypass: effects of dopamine and milrinone. *Journal of cardiothoracic and vascular anesthesia* 1999; 13: 292-8.
 327. Hamada Y, Kawachi K, Yamamoto T, Nakata T, Kashu Y, Sato M, Watanabe Y. Effects of single administration of a phosphodiesterase III inhibitor during cardiopulmonary bypass: comparison of milrinone and amrinone. *Jpn.Circ.J* 1999; 63: 605-9.
 328. Hayashida N, Kawara T, Tomoeda H, Oda T, Akasu K, Kosuga T, Chihara S, Tayama E, Kashikie H, Aoyagi S. [Influence of milrinone on internal mammary artery grafts]. *Kyobu Geka* 1999; 52: 993-7.
 329. Hayashida N, Tomoeda H, Oda T, Tayama E, Chihara S, Kawara T, Aoyagi S. Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass. *Ann.Thorac.Surg.* 1999; 68: 1661-7.

330. Lobato EB, Urdaneta F, Martin TD, Gravenstein N. Effects of milrinone versus epinephrine on grafted internal mammary artery flow after cardiopulmonary bypass. *Journal of cardiothoracic and vascular anesthesia* 2000; 14: 9-11.
331. Lobato EB, Gravenstein N, Martin TD. Milrinone, not epinephrine, improves left ventricular compliance after cardiopulmonary bypass. *J.Cardiothorac.Vasc.Anesth.* 2000; 14: 374-7.
332. Sha K, Shimokawa M, Ishimaru K, Kawaraguchi Y, Takahashi M, Yanaidani F, Kitaguchi K, Furuya H. [Differences in hemodynamic effects of amrinone, milrinone and olprinon after cardiopulmonary bypass in valvular cardiac surgery]. *Masui* 2000; 49: 981-6.
333. Yamaura K, Okamoto H, Akiyoshi K, Irita K, Taniyama T, Takahashi S. Effect of low-dose milrinone on gastric intramucosal pH and systemic inflammation after hypothermic cardiopulmonary bypass. *Journal of cardiothoracic and vascular anesthesia* 2001; 15: 197-203.
334. Iwagaki T, Irie J, Ijichi K, Uratsuji Y. [The effects of milrinone on hemodynamics in patients undergoing cardiac surgery]. *Masui* 2001; 50: 360-4.
335. Janelle GM, Urdaneta F, Blas ML, Shryock J, Tang YS, Martin TD, Lobato EB. Inhibition of phosphodiesterase type III before aortic cross-clamping preserves intramyocardial cyclic adenosine monophosphate during cardiopulmonary bypass. *Anesth Analg.* 2001; 92: 1377-83.
336. Shibata T, Suehiro S, Sasaki Y, Hosono M, Nishi S, Kinoshita H. Slow induction of milrinone after coronary artery bypass grafting. *Ann.Thorac.Cardiovasc.Surg.* 2001; 7: 23-7.
337. Zabeeda D, Medalion B, Jakobshvilli S, Ezra S, Schachner A, Cohen AJ. Comparison of systemic vasodilators: effects on flow in internal mammary and radial arteries. *Ann.Thorac.Surg.* 2001; 71: 138-41.
338. Lobato EB, Janelle GM, Urdaneta F, Martin TD. Comparison of milrinone versus nitroglycerin, alone and in combination, on grafted internal mammary artery flow after cardiopulmonary bypass: effects of alpha-adrenergic stimulation. *Journal of cardiothoracic and vascular anesthesia* 2001; 15: 723-7.
339. Mollhoff T, Schmidt C, Van Aken H, Berendes E, Buerkle H, Marmann P, Reinbold T, Prenger-Berninghoff R, Tjan TD, Scheld HH, Deng MC. Myocardial ischaemia in patients with impaired left ventricular function undergoing coronary artery bypass grafting--milrinone versus nifedipin. *Eur.J Anaesthesiol.* 2002; 19: 796-802.

340. Kikura M, Sato S. The efficacy of preemptive Milrinone or Amrinone therapy in patients undergoing coronary artery bypass grafting. *Anesth Analg.* 2002; 94: 22-30.
341. Kikura M, Sato S. Effects of preemptive therapy with milrinone or amrinone on perioperative platelet function and haemostasis in patients undergoing coronary bypass grafting. *Platelets.* 2003; 14: 277-82.
342. Kim JH, Ham BM, Kim YL, Bahk JH, Ryu HG, Jeon YS, Kim KB. Prophylactic milrinone during OPCAB of posterior vessels: implication in angina patients taking beta-blockers. *Eur.J Cardiothorac Surg.* 2003; 24: 770-6.
343. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, Bailey JM, Akbary A, Kocsis JF, Kaczmarek R, Spray TL, Wessel DL. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. *Circulation* 2003; 107: 996-1002.
344. Kwak YL, Oh YJ, Kim SH, Shin HK, Kim JY, Hong YW. Efficacy of preemptive milrinone in off-pump coronary artery bypass surgery: comparison between patients with a low and normal pre-graft cardiac index. *Eur.J Cardiothorac Surg.* 2004; 26: 687-93.
345. Kwak YL, Oh YJ, Shinn HK, Yoo KJ, Kim SH, Hong YW. Haemodynamic effects of a milrinone infusion without a bolus in patients undergoing off-pump coronary artery bypass graft surgery. *Anaesthesia* 2004; 59: 324-31.
346. Maslow AD, Regan MM, Schwartz C, Bert A, Singh A. Inotropes improve right heart function in patients undergoing aortic valve replacement for aortic stenosis. *Anesth.Analg.* 2004; 98: 891-902.
347. Khazin V, Kaufman Y, Zabeeda D, Medalion B, Sasson L, Schachner A, Ezri T. Milrinone and nitric oxide: combined effect on pulmonary artery pressures after cardiopulmonary bypass in children. *Journal of cardiothoracic and vascular anesthesia* 2004; 18: 156-9.
348. Omae T, Kakihana Y, Mastunaga A, Tsuneyoshi I, Kawasaki K, Kanmura Y, Sakata R. Hemodynamic changes during off-pump coronary artery bypass anastomosis in patients with coexisting mitral regurgitation: improvement with milrinone. *Anesth Analg.* 2005; 101: 2-8.
349. Lobato EB, Willert JL, Looke TD, Thomas J, Urdaneta F. Effects of milrinone versus epinephrine on left ventricular relaxation after cardiopulmonary bypass following myocardial revascularization: assessment by color m-mode and tissue Doppler. *Journal of cardiothoracic and vascular anesthesia* 2005; 19: 334-9.

350. Haraldsson A, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. *Anesth.Analg.* 2001; 93: 1439-45.
351. Sablotzki A, Starzmann W, Scheubel R, Grond S, Czeslick EG. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates: [La vasodilatation pulmonaire selective avec l'inhalation de milrinone en aerosol chez des candidats a la greffe cardiaque]. *Can.J Anaesth.* 2005; 52: 1076-82.
352. Buckley MS, Feldman JP. Nebulized milrinone use in a pulmonary hypertensive crisis. *Pharmacotherapy* 2007; 27: 1763-6.
353. Wang H, Gong M, Zhou B, Dai A. Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. *Adv.Ther.* 2009; 26: 462-8.
354. Lamarche Y, Malo O, Thorin E, Denault AY, Carrier M, Roy J, Perrault LP. Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass. *J.Thorac.Cardiovasc.Surg.* 2005; 130: 83-92.
355. Hentschel T, Yin N, Riad A, Habbazettl H, Weimann J, Koster A, Tschope C, Kuppe H, Kuebler WM. Inhalation of the Phosphodiesterase-3 Inhibitor Milrinone Attenuates Pulmonary Hypertension in a Rat Model of Congestive Heart Failure. *Anesthesiology* 2007; 106: 124-31.
356. Chen F, Zhang J, Aoyama A, Okamoto T, Fujinaga T, Bando T. Potential for pulmonary protection by nebulized milrinone during warm ischemia. *Transplant.Proc.* 2008; 40: 3335-8.
357. Zhang J, Chen F, Zhao X, Aoyama A, Okamoto T, Fujinaga T, Shoji T, Sakai H, Cui Y, Bando T, Date H. Nebulized phosphodiesterase III inhibitor during warm ischemia attenuates pulmonary ischemia-reperfusion injury. *J Heart Lung Transplant.* 2009; 28: 79-84.
358. Fortier S, DeMaria RG, Lamarche Y, Malo O, Denault AY, Desjardins F, Carrier M, Perrault LP. Inhaled prostacyclin reduces cardiopulmonary bypass-induced pulmonary endothelial dysfunction via increased cyclic adenosine monophosphate levels. *J.Thorac.Cardiovasc.Surg.* 2004; 128: 109-16.
359. Lamarche Y, Gagnon J, Malo O, Blaise G, Carrier M, Perrault LP. Ventilation prevents pulmonary endothelial dysfunction and improves oxygenation after cardiopulmonary bypass without aortic cross-clamping. *Eur.J Cardiothorac Surg.* 2004; 26: 554-63.

360. David TE. Is prosthesis-patient mismatch a clinically relevant entity? *Circulation* 2005; 111: 3186-7.
361. Nguyen AQ, Theoret Y, Chen C, Denault A, Varin F. High performance liquid chromatography using UV detection for the quantification of milrinone in plasma: improved sensitivity for inhalation. *J Chromatogr.B Analyt.Technol.Biomed.Life Sci.* 2009; 877: 657-60.
362. Butterworth JF, Hines RL, Royster RL, James RL. A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. *Anesth Analg.* 1995; 81: 783-92.
363. Katz SL, Adataia I, Louca E, Leung K, Humpl T, Reyes JT, Coates AL. Nebulized therapies for childhood pulmonary hypertension: an in vitro model. *Pediatr.Pulmonol.* 2006; 41: 666-73.
364. Vincens JJ, Temizer D, Post JR, Edmunds LH, Jr., Herrmann HC. Long-term outcome of cardiac surgery in patients with mitral stenosis and severe pulmonary hypertension. *Circulation* 1995; 92: II137-II142.
365. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. *J.Clin.Invest* 1985; 75: 643-9.
366. Woolfrey SG, Hegbrant J, Thysell H, Fox PA, Lendrem DW, Lockwood GF, Lasher K, Rogers J, Greenslade D. Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure. *J Pharm.Pharmacol.* 1995; 47: 651-5.
367. Lapointe V, Jocov D, Denault A. Hemodynamic instability in septic shock. *Can.J Anaesth.* 2009; 56: 864-7.
368. Feissel M, Michard F, Faller JP, Teboul JL. The respiratory variation in inferior vena cava diameter as a guide to fluid therapy. *Intensive Care Med.* 2004; 30: 1834-7.
369. Barbier C, Loubieres Y, Schmit C, Hayon J, Ricome JL, Jardin F, Vieillard-Baron A. Respiratory changes in inferior vena cava diameter are helpful in predicting fluid responsiveness in ventilated septic patients. *Intensive Care Med.* 2004; 30: 1740-6.
370. Vieillard-Baron A, Chergui K, Rabiller A, Peyrouset O, Page B, Beauchet A, Jardin F. Superior vena caval collapsibility as a gauge of volume status in ventilated septic patients. *Intensive Care Med.* 2004; 30: 1734-9.

371. HILL AB. The environment and disease: association or causation? *Proc.R.Soc.Med.* 1965; 58: 295-300.
372. Rackow EC, Astiz ME. Pathophysiology and treatment of septic shock. *JAMA* 1991; 266: 548-54.
373. Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F. Actual incidence of global left ventricular hypokinesia in adult septic shock. *Crit Care Med.* 2008; 36: 1701-6.
374. Regueira T, Bruhn A, Hasbun P, Aguirre M, Romero C, Llanos O, Castro R, Bugeo G, Hernandez G. Intra-abdominal hypertension: incidence and association with organ dysfunction during early septic shock. *J Crit Care* 2008; 23: 461-7.
375. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N.Engl.J Med.* 2003; 348: 1546-54.
376. De BD, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow is altered in patients with sepsis. *Am.J Respir.Crit Care Med.* 2002; 166: 98-104.
377. Sakr Y, Dubois MJ, De BD, Creteur J, Vincent JL. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. *Crit Care Med.* 2004; 32: 1825-31.
378. Trzeciak S, Dellinger RP, Parrillo JE, Guglielmi M, Bajaj J, Abate NL, Arnold RC, Colilla S, Zanotti S, Hollenberg SM. Early microcirculatory perfusion derangements in patients with severe sepsis and septic shock: relationship to hemodynamics, oxygen transport, and survival. *Ann.Emerg.Med.* 2007; 49: 88-98.
379. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N.Engl.J Med.* 2001; 345: 1368-77.
380. Pearse R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial [ISRCTN38797445]. *Crit Care* 2005; 9: R687-R693.
381. Donati A, Loggi S, Preiser JC, Orsetti G, Munch C, Gabbanelli V, Pelaia P, Pietropaoli P. Goal-directed intraoperative therapy reduces morbidity and length of hospital stay in high-risk surgical patients. *Chest* 2007; 132: 1817-24.

382. Polonen P, Ruokonen E, Hippelainen M, Poyhonen M, Takala J. A prospective, randomized study of goal-oriented hemodynamic therapy in cardiac surgical patients. *Anesth Analg.* 2000; 90: 1052-9.
383. Bersin RM, Wolfe C, Kwasman M, Lau D, Klinski C, Tanaka K, Khorrami P, Henderson GN, De MT, Chatterjee K. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. *J Am.Coll.Cardiol.* 1994; 23: 1617-24.
384. Iliceto S, Scrutinio D, Bruzzi P, D'Ambrosio G, Boni L, Di BM, Biasco G, Hugenholtz PG, Rizzon P. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. *J Am.Coll.Cardiol.* 1995; 26: 380-7.
385. Tarantini G, Scrutinio D, Bruzzi P, Boni L, Rizzon P, Iliceto S. Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. *Cardiology* 2006; 106: 215-23.
386. Ventetuolo CE, Benza RL, Peacock AJ, Zamanian RT, Badesch DB, Kawut SM. Surrogate and combined end points in pulmonary arterial hypertension. *Proc.Am.Thorac.Soc.* 2008; 5: 617-22.
387. Deschamps A, Denault A. Analysis of heart rate variability: a useful tool to evaluate autonomic tone in the anesthetized patient? *Can.J.Anaesth.* 2008; 55: 208-13.
388. Deschamps A, Denault A. Autonomic nervous system and cardiovascular disease. *Semin.Cardiothorac.Vasc.Anesth* 2009; 13: 99-105.
389. Yu FT, Cloutier G. Experimental ultrasound characterization of red blood cell aggregation using the structure factor size estimator. *J Acoust.Soc.Am.* 2007; 122: 645-56.
390. Franceschini E, Yu FT, Cloutier G. Simultaneous estimation of attenuation and structure parameters of aggregated red blood cells from backscatter measurements. *J Acoust.Soc.Am.* 2008; 123: EL85-EL91.

Abbreviations

2D	two-dimensional
A dur	duration of mitral inflow A-wave
A	peak late or atrial diastolic flow velocity
ABC	Airway-Breathing-Circulation
AC	aortic occlusion
ACC/AHA	American College of Cardiology and American Heart Association
ACE	angiotensin converting enzyme
ACS	abdominal compartment syndrome
Am	atrial mitral annular velocity
AML	anterior mitral leaflet length
AMP	adenosine monophosphate
ANCOVA	analysis of covariance
ANOVA	analysis of variance
Ao	aorta
AoV	aortic valve
AP	arterial pressure
APP	abdominal perfusion pressure
AR	aortic regurgitation
AR	atrial reversal
ASD	atrial septal defect
At	atrial tricuspid annular velocity
AVR	aortic valve replacement
BART	Blood Conservation Using Antifibrinolytics in a Randomized Trial
BMI	body mass index
BP	blood pressure
BSA	body surface area

CABG	coronary artery bypass grafting
CAD	coronary artery disease
CARE	Cardiac Anesthesia Risk Evaluation
CASS	Coronary Artery Surgery Study
CBF	cerebral blood flow
CHF	congestive heart failure
CI	cardiac index
CI	confidence interval
CK	creatinine kinase
CO	cardiac output
COPD	chronic obstructive pulmonary disease
CPB	cardiopulmonary bypass
CTICU	cardiothoracic intensive care unit
CVD	cerebrovascular disease
CVP	central venous pressure
D	diastolic
DAP	diastolic arterial pressure
DPAP	diastolic pulmonary arterial pressure
DSB	difficult separation from bypass
DT	deceleration time
E	early
ECMO	extra-corporeal membrane oxygenator
EDA	end-diastolic area
EDV	end-diastolic volume
EF	ejection fraction
EKG	electrocardiogram
Em	early mitral annular velocity
EOA	effective orifice area
ESA	end-systolic area

ESV	end-systolic volume
Et	early tricuspid annular velocity
ET	ejection time
FAC	fractional area change
Fem	Femoral
FRC	functional residual capacity
Gd	gradient
GEE	generalized estimating equation
HR	heart rate
HVF	hepatic venous flow
IABP	intra-aortic balloon pump
IAH	intra-abdominal hypertension
IAP	intra-abdominal pressure
ICU	intensive care unit
iEOA	indexed effective orifice area
IL	interleukin
iMil	Inhaled milrinone
iNO	inhaled nitric oxide
iPGI ₂	inhaled prostacyclin
IU	international unit;
IV	intravenous
IVC	interior vena cava
IVCT	isovolumic contraction time
IVRT	isovolumic relaxation time
LA	left atrium
LAA	left atrial appendage
LADt	left atrial transverse dimension
LAP	left atrial pressure
LCOS	low cardiac output syndrome

LHV	left hepatic vein
LIJV	left internal jugular vein
LIMA	left internal mammary artery
LOF	low output failure
LUPV	left upper pulmonary vein
LV	left ventricle or left ventricular
LVAD	left ventricular assist device
LVDD	left ventricular diastolic dysfunction
LVEDA	left ventricular end-diastolic area
LVEDP	left ventricular end-diastolic pressure
LVEF	left ventricular ejection fraction
LVESA	left ventricular end-systolic area
LVFAC	left ventricular fractional area change
LVOT	left ventricular outflow tract
LVOTO	left ventricular outflow tract obstruction
LVWMSI	left ventricular wall motion score index
MAP	mean arterial pressure
MAV	mitral annular velocity
MHI	Montreal Heart Institute
MI	myocardial infarction
MPAP	mean pulmonary artery pressure
MPI	myocardial performance index
MR	mitral regurgitation
MV	mitral valve
MVO ₂	mixed venous oxygen
MVR	mitral valve replacement
NIH	National Institute of Health
NIRS	near-infrared spectroscopy
NO	nitric oxide

NTG	nitroglycerin
NTP	nitroprusside
NYHA	New York Heart Association
OM	obtuse marginal
OR	odds ratio
OR	operating room
Pa	arterial pressure
PA	pulmonary artery
PAC	pulmonary artery catheter
Paf	femoral arterial pressure
PAF	platelet activating factor
PAP	pulmonary artery pressure
Par	radial arterial pressure
PCWP	pulmonary capillary wedge pressure
PEEP	positive end-expiratory pressure
PFO	patent foramen ovale
PGE ₁	prostaglandin E ₁
PGI ₂	prostacyclin
PH	pulmonary hypertension
PML	posterior mitral leaflet length
Pms	mean systemic pressure
PMV	prosthetic mitral valve
PN	pseudonormal
Ppa	pulmonary artery pressure
PPM	patient-prosthesis mismatch
Pra	right atrial pressure
Prv	right ventricular pressure
PVF	pulmonary venous flow
PVR	pulmonary vascular resistance

PVRI	indexed pulmonary vascular resistance
PW	pulsed-wave
QHLI	Quebec Heart and Lung Institute
Ra	arterial resistance
RA	relaxation abnormality
RA	right atrium
Rad	Radial
RADt	right atrial transverse diameter
RBC	red blood cell;
RCA	right coronary artery
RCT	randomized controlled trial
ROC	receiver operating characteristics
RPA	right pulmonary artery
Rrv	resistance to venous return
RV	residual volume
RV	right ventricle or right ventricular
RVAD	right ventricular assist device
RVDD	right ventricular diastolic dysfunction
RVED	right ventricular end-diastolic volume
RVEDA	right ventricular end-diastolic area
RVEF	right ventricular ejection fraction
RVES	right ventricular end-systolic volume
RVESA	right ventricular end-systolic area
RVFAC	right ventricular fractional area change,
RVMPI	right ventricular myocardial performance index
RVOT	right ventricular outflow tract
RVOTO	right ventricular outflow tract obstruction
Rvr	resistance to venous return
RWMA	regional wall motion abnormalities

RWMSI	regional wall motion score index
S	systolic
SAM	systolic anterior motion
SAP	systemic arterial pressure
ScO ₂	cerebral oxygen saturation
SCV	subclavian vein
SD	standard deviation;
SE	standard error
Sec	seconds
SLCL	septal to leaflet coaptation length
Sm	systolic mitral annular velocity
SPAP	systolic pulmonary artery pressure
St	systolic tricuspid annular velocity
STS	Society of Thoracic Surgeons
SV	stroke volume
SVC	superior vena cava
SVR	systemic vascular resistance
SVRI	indexed systemic vascular resistance
TAPSE	tricuspid annular plane systolic excursion
TAV	tricuspid annular velocity
TD	thermodilution
TDI	tissue Doppler imaging
TEE	transesophageal echocardiography
TLC	total lung capacity
TMF	transmitral flow
TNF	tumor necrosis factor
TO ₂	oxygen transport
TTF	transtricuspid flow
TV	tricuspid valve

UK	United Kingdom
USA	United States of America
VAD	ventricular assist device
Vp	velocity of propagation
VR	venous return